Introduction {#s1}
============

HIV infection is known to result in extensive T cell depletion in lymph node environments ([@bib56]), where infection is most robust ([@bib8]; [@bib18]; [@bib19]; [@bib22]; [@bib25]; [@bib42]). Depletion of HIV infectable target cells, in addition to onset of immune control, is thought to account for the decreased replication ratio of HIV from an initial peak in early infection ([@bib5]; [@bib45]; [@bib48]; [@bib49]; [@bib50]; [@bib53]; [@bib68]). This is consistent with observations that individuals are most infectious in the initial, acute stage of infection, where the target cell population is relatively intact and produces high viral loads ([@bib31]; [@bib65]).

T-cell death occurs by several mechanisms, which are either directly or indirectly mediated by HIV infection. Accumulation of incompletely reverse transcribed HIV transcripts is sensed by interferon-γ--inducible protein 16 ([@bib43]) and leads to pyroptotic death of incompletely infected cells by initiating a cellular defence program involving the activation of caspase 1 ([@bib18]; [@bib19]; [@bib25]). HIV proteins Tat and Env have also been shown to lead to cell death of infected cells through CD95-mediated apoptosis following T-cell activation ([@bib2]; [@bib66]; [@bib67]). Using SIV infection, it has been shown that damage to lymph nodes due to chronic immune activation leads to an environment less conducive to T-cell survival ([@bib70]). Finally, double strand breaks in the host DNA caused by integration of the reverse transcribed virus results in cell death by the DNA-PK-mediated activation of the p53 response ([@bib11]).

The lymph node environment is conducive to HIV infection due to: (1) presence of infectable cells ([@bib15]; [@bib21]; [@bib63]); (2) proximity of cells to each other and lack of flow which should enable cell-to-cell HIV spread ([@bib3]; [@bib12]; [@bib28]; [@bib29]; [@bib30]; [@bib32]; [@bib34]; [@bib35]; [@bib44]; [@bib58]; [@bib60]; [@bib61]); (3) decreased penetration of antiretroviral therapy (ART) ([@bib23]). Multiple infections per cell have been reported in cell-to-cell spread of HIV ([@bib3]; [@bib7]; [@bib13]; [@bib14]; [@bib17]; [@bib20]; [@bib40]; [@bib51]; [@bib54]; [@bib59]; [@bib71]). In this mode of HIV transmission, an interaction between the infected donor cell and the uninfected target results in directed transmission of large numbers of virions ([@bib3]; [@bib29]; [@bib32]; [@bib61]). This is in contrast to cell-free infection, where free-floating virus finds target cells through diffusion. Both modes occur simultaneously when infected donor cells are cocultured with targets. However, the cell-to-cell route is thought to be the main cause of multiple infections per cell ([@bib32]). In the lymph nodes, several studies showed multiple infections ([@bib27]; [@bib38]; [@bib40]) while another study did not ([@bib37]). One explanation for the divergent results is that different cell subsets are infected to different degrees. For example, T cells were shown not to be multiply infected in the peripheral blood compartment ([@bib36]). However, more recent work investigating markers associated with HIV latency in the face of ART found that the average number of HIV DNA copies per cell is greater than one in 3 out of 12 individuals. This occurred in the face of ART in the CD3-positive, CD32a high CD4 T-cell subset ([@bib16]). In the absence of suppressive ART, it would be expected that the number of HIV DNA copies per cell would be higher.

Multiple viral integration attempts per cell may increase the probability of death. One consequence of HIV-mediated death may be that attenuation of infection may increase viral replication by increasing the number of live targets. Indeed, it has been suggested that more attenuated HIV strains result in more successful infections in terms of the ability of the virus to replicate in the infected individual ([@bib1]; [@bib45]; [@bib47]; [@bib50]; [@bib68]).

Here, we experimentally examined the effect of attenuating cell-to-cell spread by using HIV inhibitors. We observed that partially inhibiting infection with drug or antibody resulted in an increase in the number of live infected cells in both a cell line and in lymph node cells. This is, to our knowledge, the first experimental demonstration at the cellular level that attenuation of HIV infection can result in an increase in live infected cells under specific infection conditions.

Results {#s2}
=======

We introduce a model of infection where each donor to target transmission leads to an infection probability *r* and death probability *q* per infection attempt. In our experimental system, one infection attempt is measured as one HIV DNA copy, whether integrated or unintegrated. The probability of successful infection of a target cell given *n* infection attempts is *1-(1 r)^n^* ([@bib59]). We define *L~n~* as the probability of a cell to survive infection in the face of *n* infection attempts. Assuming infection attempts act independently, *L~n~*=*(1-q)^n^*. The probability of a cell to be infected and not die after it has been exposed to *n* infection attempts is therefore:$$P_{n} = \left( {1 - \left( {1 - r} \right)^{n}} \right)\left( {1 - q} \right)^{n}$$

This model makes several simplifying assumptions: (1) all infection attempts have equal probabilities to infect targets. (2) The probability for a cell to die from each transmission is equal between transmissions. (3) Infection attempts act independently, and productive infection and death are independent events. In this model, *r* and *q* capture the probabilities for a cell to be infected or die post-reverse transcription. For example, mutations which reduce viral fitness by decreasing the probability of HIV to integrate would reduce *r*, while mutations which reduce the probability of successful reverse transcription would reduce *n*.

If the number of infection attempts *n* is Poisson distributed with mean *λ*, the probability for a cell to be infected is *1-e^-rλ^* and the probability of a cell to live is *L~n~* = *e^-qλ^* (see [Supplementary file 1](#supp1){ref-type="supplementary-material"} for parameters and definitions). As derived in Appendix 1, the probability that a cell is productively infected will be:$$\left. {P_{\lambda} = e}^{- \lambda q}\left( 1 - e \right.^{- \lambda r(1 - q)} \right)$$

Since antiretroviral drugs lead to a reduction in the number of infection attempts by, for example, decreasing the probability of reverse transcription in the case of reverse transcriptase inhibitors, we introduced a drug strength value *d*, where *d = 1* in the absence of drug and *d \> 1* in the presence of drug. In the presence of drug, *λ* is decreased to λ*/d*. The drug therefore tunes *λ*, and if the antiretroviral regimen is fully suppressive, *λ/d* is expected to be below what is required for ongoing replication. The probability of a cell to be infected and live given drug strength *d* is therefore:$$\left. {P_{\lambda/d} = e}^{- \lambda q/d}\left( 1 - e \right.^{- \lambda r(1 - q)/d} \right)$$

Analysis of the probability of a cell to survive and be infected as a function of *r* and *q* shows that at each drug strength *d/λ*, *P~λ~* increases as the probability of infection *r* increases ([Figure 1](#fig1){ref-type="fig"}). Hence, the value of *r* strongly influences the amplitude of *P~λ~*. How *P~λ~* behaves when drug strength *d/λ* increases depends on the parameter values of *r* and *q*. A subset of parameter values results in a peak in the number of infected cells at intermediate *d/λ*, decreasing as drug strength increases further ([Figure 1](#fig1){ref-type="fig"}). We refer to such a peak in infected numbers as an infection optimum. As *q* increases, the cost of multiple infections per cell increases, and the infection optimum shifts to higher *d/λ* values. A fall from the infection optimum at decreasing *d/λ* is driven by increasing cell death as a result of increasing infection attempts per cell. This slope is therefore shallower, and peaks broader, at low *q* values ([Figure 1](#fig1){ref-type="fig"}).

![Probability for a cell to be infected and live as a function of inhibitor.\
Probability for a cell to be infected and live was calculated for 20 infection attempts (*λ*) and represented as a heat map. Drug strength (*d/λ)* is on the y-axis, and the probability per infection attempt to infect (**r**) is on the x-axis. Each plot is the calculation for one value of the probability per infection attempt to die (**q**) denoted in white in the top left corner.](elife-30134-fig1){#fig1}

Our model assumes that cellular infection and death due to an HIV infection attempt are independent processes. This is based on observations that support a role for cell death as a cellular defence mechanism which may occur before productive infection, such as programmed cell death triggered by HIV integration induced DNA damage ([@bib11]). An alternative model is that HIV-mediated cell death depends on productive infection. This would be consistent with cell death due to, for example, expression of viral proteins ([@bib67]). Since the concentration of viral proteins may also scale with the number of infections per cell, we derived the mathematical model for such a process in the supplementary mathematical analysis. The models are equivalent, showing that independence of cell death and infection is not a necessary condition for an infection optimum to occur in the presence of inhibitor.

Given that an infection optimum is dependent on parameter values, we next examined whether these parameter values occur experimentally in HIV infection. We therefore first tested for an infection optimum in the RevCEM cell line engineered to express GFP upon HIV Rev protein expression ([@bib69]). We subcloned the cell line to maximize the frequency of GFP-positive cells upon infection ([@bib7]). We needed to detect the number of infection attempts per cell *λ*. To estimate this, we used PCR to detect the number of reverse transcribed copies of viral DNA in the cell by splitting each individual infected cell over multiple wells. We then detected the number of wells with HIV DNA by PCR amplification of the reverse transcriptase gene. Hence, the number of positive wells indicated the minimum number of viral DNA copies per cell, since more than one copy can be contained within the same well ([@bib36]; [@bib37]). We first measured the number of viral DNA copies in ACH-2 cells, reported to contain a single inactive HIV integration per genome ([@bib10]; [@bib46]). We sorted a total of 166 ACH-2 cells at one cell per well into lysis buffer and subdivided single-cell lysates into four wells ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). About one quarter of cells showed a PCR product of the expected size. Cells with more than one HIV copy per cell were very rare and may reflect either errors in cell sorting or dividing cells ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). Similar frequencies were obtained when the ACH-2 cell line was subcloned or split over 10 wells ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). Given that each ACH-2 cell contains one HIV DNA copy, the frequency of detection indicated our detection efficiency per HIV DNA copy.

To investigate the effect of multiple infection attempts per cell, we used coculture infection, where infected (donor) cells are co-incubated with uninfected (target) cells and lead to cell-to-cell spread. We used approximately 2% infected donor cells as our input, and detected the number of HIV DNA copies per cell by flow cytometric sorting of individual GFP-positive cells followed by splitting each cell lysate over 10 wells. Wells were then amplified by PCR and visualized on an agarose gel ([Figure 2A](#fig2){ref-type="fig"}). We assayed 60 cells and obtained a wide distribution of viral DNA copies per cell, which ranged from 0 to 9 copies ([Figure 2B](#fig2){ref-type="fig"}). The range of HIV DNA copies per cell fit a Poisson distribution with two means better than either a single mean Gaussian or Poisson distribution. However, the fit of the two mean Poisson distribution did not show two obvious peaks, and instead seemed to fit the data better due to the addition of fit parameters ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Hence we cannot conclude that the distribution is bimodal. We also detected the HIV copy number in 30 GFP-positive cells infected by cell-free HIV. HIV in cell-free form was obtained by filtering supernatant from HIV producing cells to exclude cells or cell fragments, then infecting target cells with the filtered virus. Infection with this virus is defined here as cell-free infection. In this case, we detected either zero or one HIV copy per cell ([Figure 2B](#fig2){ref-type="fig"} inset). The frequency of single HIV DNA copies was 0.23, identical to the measured result in the ACH-2 cell line. We computationally corrected the detected number of DNA copies in coculture infection for the sensitivity of our PCR reaction as determined by the ACH-2 results (Materials and methods). On average we obtained 15 ± 3 copies per cell after correction.

![Partial inhibition increases the number of live infected cells.\
(**A**) To quantify HIV DNA copy number per cell, GFP-positive cells were sorted into individual wells and lysed. Each lysate was subdivided into 10 wells and PCR performed to detect HIV DNA, with the sum of positive wells being the raw HIV copy number for that cell. (**B**) Histogram of raw HIV DNA copies per cell in coculture infection (n = 60 cells, four independent experiments). Inset shows raw HIV DNA copies per cell in cell-free infection (n = 30, two independent experiments) (**C**) Number of live infected cells normalized by maximum number of live infected cells in cell-free infection with EFV. Black line is best-fit for EFV suppression of cell-free infection (IC~50~ = 2.9 nM, h = 2.1). Means and standard errors for three independent experiments. (**D**) Number of live infected cells/ml 2 days post-infection resulting from coculture infection of 10^6^ cells/ml in the presence of EFV. Means and standard errors for three independent experiments. Black line is best-fit of [Equation (3)](#equ3){ref-type="disp-formula"} with *r* = 0.22 and *q* = 0.17. Dashed green line is the result of [Equation (3)](#equ3){ref-type="disp-formula"} with experimentally measured *r* = 0.28, *q* = 0.15.](elife-30134-fig2){#fig2}

To tune *λ*, we added the HIV reverse transcriptase inhibitor efavirenz (EFV) to infections. To calculate *d*, we used cell-free infection ([Figure 2C](#fig2){ref-type="fig"}, see [Figure 2---figure supplement 3](#fig2s3){ref-type="fig"} for logarithmic y-axis plot), which as verified above, results in single HIV copies per cell. For cell-free infection, we approximate *d = 1/Tx,* where *Tx* is defined as the number of infected cells with drug divided by the number of infected cells without drug with single infection attempts (see Materials and methods and \[([@bib59]\]). This is equivalent to 1-ε in a commonly used model describing the effect of inhibitors on infection. In this model, ε is drug effectiveness, with the 50% inhibitory drug concentration (IC~50~) and the Hill coefficient for drug action as parameter values ([@bib9]; [@bib57]). We fit the observed response of infection to EFV using this approach to estimate *d* across a range of EFV concentrations. Fit of the model to the cell-free data using wild type, EFV-sensitive HIV showed a monotonic decrease with IC~50~ = 2.9 nM and Hill coefficient of 2.1 ([Figure 2C](#fig2){ref-type="fig"}, black line).

We next dialed in EFV to tune *λ/d* in coculture infection. To obtain the number of infected target cells, and specifically exclude donor cells or donor-target cell fusions, target cells were marked by the expression of mCherry. Donor cells were stained with the vital stain Cell Trace Far Red (CTFR). The concentration of live infected cells was determined after 2 days in coculture with infected donors. Live infected cells were identified based on the absence of cell death indicator dye DAPI fluorescence, and presence of GFP. The input of infected donor cells was excluded from the count of infected cells based on the absence of mCherry fluorescence. Donor-target cell fusions were excluded by excluding CTFR-positive cells (see [Figure 2---figure supplement 4](#fig2s4){ref-type="fig"} for gating strategy).

While the percent of infected cells was reduced with drug, the concentration of live infected cells increased ([Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}). We observed a peak in the number of live infected target cells at 4 nM EFV ([Figure 2D](#fig2){ref-type="fig"}). We then fit the number of live infected cells using [Equation (3)](#equ3){ref-type="disp-formula"}, where *P~λ~* was multiplied by the input number of target cells per ml (10^6^ cells/ml) to obtain the predicted number of live infected cells per ml of culture. This was done to constrain *r* in the model, which strongly determines the amplitude of *P~λ/d~* as described above. [Equation (3)](#equ3){ref-type="disp-formula"} best fit the behaviour of infection when *r* = 0.22 *and q* = 0.17, resulting in a peak at 4.8 nM EFV ([Figure 2D](#fig2){ref-type="fig"}, black line). Hence an infection optimum is present in the cell line infection system.

In order to determine whether the fitted *r* and *q* values were within a reasonable range, we measured these values experimentally. To measure *r*, we infected with cell-free HIV to avoid the broad distribution of HIV copy numbers observed in cell-to-cell spread, and determined the fraction of live infected cells *P~λ~* ([Figure 2---figure supplement 5A](#fig2s5){ref-type="fig"}). We then determined the mean number of HIV copies per cell *λ* for the same set of experiments corrected by the efficiency of detection ([Figure 2---figure supplement 5B](#fig2s5){ref-type="fig"}). The parameter *r* was calculated as *-ln(1-P~λ~)/λ* ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). To measure *q*, we blocked cell division using serum starvation to measure differences in cell concentration due to cell death only, and not due to proliferation of uninfected cells ([Figure 2---figure supplement 5C](#fig2s5){ref-type="fig"}). We then infected with cell-free HIV and measured *L~λ~*, defined as the fraction of live cells remaining upon infection with *λ* HIV DNA copies relative to infection blocked with EFV (see below). To specifically detect the decrease in live cells as a result of events downstream of reverse transcription, we compared infected cells to cells exposed to the same virus concentration but treated with 40 nM EFV, a drug concentration where infection by cell-free virus is negligible ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). *q* was then calculated as *-ln(L~λ~)/λ,* where *L~λ~* was the probability of a cell to live given transmission with *λ* copies ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). Measured *r* and *q* values were 0.28 ± 0.08 and 0.15 ± 0.07 (mean ±standard deviation), respectively. The solution to [Equation (3)](#equ3){ref-type="disp-formula"} using these values showed similar behavior to the solution with the fitted values for wild-type HIV infection, indicating that the fitted values gave a reasonable approximation of the behavior of the system ([Figure 2D](#fig2){ref-type="fig"}, dashed green line).

In order to investigate the dynamics of cell depletion due to cell-to-cell HIV spread and its modulation by the addition of an inhibitor, we performed time-lapse microscopy over a two day infection window. While infection parameters were different due to the constraints of visualizing cells (Materials and methods), the general trend from the data was deterioration in the number of live cells in the time-lapse culture starting at 1 day post-infection when no drug was added. The deterioration in live cell numbers was averted by the addition of EFV ([Figure 2---figure supplement 6](#fig2s6){ref-type="fig"}).

We next investigated whether an infection optimum occurs with EFV-resistant HIV. To derive the resistant mutant, we cultured wild-type HIV in our reporter cell line in the presence of EFV. We obtained the L100I partially resistant mutant. We then replaced the reverse transcriptase of the wild-type molecular clone with the mutant reverse transcriptase gene (Materials and methods). We derived *d~mut~* for the L100I mutant using cell-free mutant infection ([Figure 3A](#fig3){ref-type="fig"}, see [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} for logarithmic y-axis plot). The L100I mutant was found to have an IC~50~ = 29 nM EFV and a Hill coefficient of 2.0 ([Figure 3A](#fig3){ref-type="fig"}, black line).

![Partial inhibition of the EFV-resistant L100I mutant shifts the peak of live infected cells to higher EFV concentrations.\
(**A**) The number of live infected cells normalized by the maximum number of live infected cells in cell-free infection as a function of EFV for the L100I mutant. Black line is best-fit for EFV suppression of cell-free infection (IC~50~ = 29 nM, h = 2.0). Shown are means and standard errors for three independent experiments. (**B**) Number of live infected cells/ml 2 days post-infection resulting from coculture infection of 10^6^ cells/ml in the presence of EFV. Means and standard errors for three independent experiments. Black line is best-fit of [Equation (3)](#equ3){ref-type="disp-formula"} with *r* = 0.29 and *q* = 0.13. Dashed green line is the result of [Equation (3)](#equ3){ref-type="disp-formula"} with the experimentally measured *r* = 0.28 and *q* = 0.15 for wild-type HIV infection.](elife-30134-fig3){#fig3}

We next performed coculture infection (see [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"} for gating strategy). Similarly to wild-type HIV coculture infection, there was a peak in the number of live infected target cells for the L100I mutant infection. However, the peak in live infected cells was shifted to 40 nM EFV ([Figure 3B](#fig3){ref-type="fig"}). Fits were obtained to [Equation (3)](#equ3){ref-type="disp-formula"} using *d~mut~* values and *λ* measured for wild-type infection. The fits recapitulated the experimental results when *r* = 0.29 and *q* = 0.13, with a fitted peak at 45 nM EFV ([Figure 3B](#fig3){ref-type="fig"}, black line). The solution to [Equation (3)](#equ3){ref-type="disp-formula"} using the measured values for *r* and *q* showed a similar pattern to that obtained with the fitted values ([Figure 3B](#fig3){ref-type="fig"}, dashed green line). We note that both wild type and mutant coculture infection has data points above the fit line at the highest drug concentrations. This may be a limitation of our model at drug values much higher than observed at the infection optimum. In this range of drug values, our model predicts a more pronounced decline in the number of infected cells than is observed experimentally.

In order to examine whether a peak in live infected targets can be obtained with an unrelated inhibitor, we used the HIV neutralizing antibody b12. This antibody is effective against cell-to-cell spread of HIV ([@bib3]; [@bib51]). We obtained a peak in live infected cells at 5 ug/ml b12 ([Figure 4](#fig4){ref-type="fig"}). The b12 concentration that resulted in a peak number of live infected cells was the same for wild-type virus and the L100I mutant, showing that L100I mutant fitness gain was EFV specific. In contrast, cell-free infection in the face of b12 showed a sharp and monotonic drop in live infected cells for both wild type and mutant virus ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}).

![Partial inhibition of coculture infection with neutralizing antibody results in higher numbers of live infected cells.\
Shown are the numbers of live infected cells normalized by the maximum number of live infected cells in coculture infection as a function of b12 antibody concentration. Infection was by either EFV-sensitive HIV (blue) or the L100I EFV-resistant mutant (green). Dashed lines are a guide to the eye. Shown are means and standard errors for three independent experiments.](elife-30134-fig4){#fig4}

While the RevCEM cell line is a useful tool to illustrate the principles governing the formation of an infection optimum, the sensitivity of such an optimum to parameter values would make its presence in primary HIV target cells speculative. We therefore investigated whether a fitness optimum occurs in primary human lymph node cells, the anatomical site which would be most likely to have a high force of infection. We derived human lymph nodes from HIV-negative individuals from indicated lung resections ([Supplementary file 3](#supp3){ref-type="supplementary-material"}), cellularized the lymph node tissue using mechanical separation, and infected the resulting lymph node cells with HIV. A fraction of the cells was infected by cell-free virus and used as infected donor cells. We added these to uninfected target cells from the same lymph node to test coculture infection, and detected the number of live infected cells 4 days post-infection with the L100I EFV-resistant mutant in the face of EFV. We detected the number of live infected cells by the exclusion of dead cells with the fixable death detection dye eFluor660 followed by single cell staining for HIV Gag using anti-p24 antibody ([Figure 5A](#fig5){ref-type="fig"}).

![Infection optimum with EFV in lymph node cells.\
(**A**) Number of live infected cells as a function of EFV. Each row shows in vitro infected lymph node cells from one participant. Left column is the number of live infected cells normalized by maximum number of live infected cells in coculture infection. Middle and right columns are flow cytometry dot plots of infection without drug and at the infection optimum, with HIV p24 on x-axis and death detection by eFluor660 on y-axis. Infected live cells are bottom right. Number in brackets represents live infected cell density per ml. PID, participant identification number. For PID205 and 257, cells were sufficient for one experiment. For PID251, means and standard errors for three independent experiments are shown. Dashed lines are a guide to the eye. (**B**) HIV DNA copy number per cell was quantified by sorting fixed p24-positive cells from PID251 into individual wells. Cells were lysed and de-crosslinking performed. Each lysate was divided into four wells and PCR performed to detect HIV DNA. First row is representative of cells with no drug, second row is representative of 40 nM EFV. (**C**) Mean and standard error of the number of HIV DNA copies without drug and with 40 nM EFV after assay sensitivity correction. N = 56 cells from three independent experiments for each condition. \*\*\*\*p=4×10^−9^, two tailed t-test.](elife-30134-fig5){#fig5}

In each of the lymph nodes tested, we observed a peak in live infected cells at intermediate EFV concentrations. Lymph node cells from participant 205 showed a peak of live infected cells at 100 nM EFV ([Figure 5A](#fig5){ref-type="fig"}, first row). The infection optimum in the lymph node cells of study participant 257 was visible as a plateau between 50 and 200 nM EFV. In the presence of EFV, there was a decrease in the fraction of dead cells that was offset by a similar increase in the fraction of live infected cells for lymph nodes from all participants. There were more overall detectable cells with EFV, resulting in differences in the absolute concentrations of live infected cells being larger than the differences in the fractions of live infected cells between EFV and non-drug-treated cells (right two columns in [Figure 5A](#fig5){ref-type="fig"}, with absolute number of live infected cells shown in parentheses in the flow cytometry plots). This is most likely due to cells which died early becoming fragments and so being excluded from the total population in the absence of EFV. Peaks in the number of live infected cells in the face of drug may be specific to lymph node derived cells. Cell-to-cell infection of peripheral blood mononuclear cells (PBMC) with wild-type HIV showed a slight peak at a very low EFV concentration in cells from one blood donor, which was not repeated in cells from two other donors ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}).

We used a lymph node from study participant 251, where we obtained more cells, to examine the number of HIV DNA copies per cell. Cells from this lymph node showed an infection optimum at 50 nM EFV ([Figure 5A](#fig5){ref-type="fig"}, third row). To detect the effect of EFV on integrations per cell, we sorted single cells based on p24-positive signal, de-crosslinked to remove the fixative (Materials and methods), then divided each cell lysate into four wells. Using fewer wells saved reagents without changing sensitivity, as demonstrated in the ACH-2 cell line ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). We detected HIV DNA copies by PCR 2 days post-infection. We observed multiple DNA copies in EFV-untreated lymph node cells. The number of copies decreased with EFV ([Figure 5B](#fig5){ref-type="fig"}). We corrected for sensitivity of detection as quantified in ACH-2 cells (Materials and methods). The corrected numbers were 21 HIV DNA copies with no drug, and five copies in the presence of EFV at the infection optimum ([Figure 5C](#fig5){ref-type="fig"}, see [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"} for histograms of raw HIV DNA copy numbers per cell). Hence, the decrease in the number of copies still results in sufficient copies to infect the cell.

Since L100I does not often occur in the absence of other drug resistance mutations according to the Stanford HIV Drug Resistance Database ([@bib52]), we repeated the experiment with the K103N mutant, a frequently observed mutation in virologic failure with a higher level of resistance to EFV relative to the L100I mutant. We used cell-free infection to obtain drug inhibition per virion at each level of EFV, which we denote *d~103~* ([Figure 6A](#fig6){ref-type="fig"}, see [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"} for logarithmic y-axis plot). The fits showed a monotonic decrease with IC~50~ = 26.0 nM and Hill coefficient of 1.5 ([Figure 6A](#fig6){ref-type="fig"}, black line). We then proceeded to use the K103N mutant in coculture infection, using cells from two different lymph nodes in different experiments (see [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"} for results of individual experiments). We observed an infection optimum with EFV in lymph node cells. The peak in the number of live infected cells in the presence of drug was between 80 and 160 nM EFV ([Figure 6B](#fig6){ref-type="fig"}). We fit the experimental data with [Equation (3)](#equ3){ref-type="disp-formula"} using *d~103~* values and the number of DNA copies in the absence of drug measured for L100I infection. We did not calculate the predicted number of infected cells for *P~λ/d~* values since the lymph node is a complex environment containing different cell subsets ([@bib55]) and the number of infectable target cells at the start of infection is difficult to determine. Hence, we normalized both the experimental number of live infected cells and the *P~λ/d~* values from [Equation (3)](#equ3){ref-type="disp-formula"} to the maximum value in each case. The fits recapitulated the experimental results when *r* = 0.91 and *q* = 0.15, with a fitted peak at 90 nM EFV ([Figure 6B](#fig6){ref-type="fig"}, black line). The *q* value matched the measured result in the cell line, while the *r* value was much higher. However, the fitted *r* value in this case is not expected to be accurate since we were unable to constrain it with the number of infected cells relative to the starting number of target cells.

![Infection with the K103N mutant shows an infection optimum at clinically observed lymph node EFV concentrations.\
(**A**) The number of live infected cells normalized by the maximum number of live infected cells in cell-free infection as a function of EFV for the K103N mutant. Black line is best-fit for EFV suppression of cell-free infection (IC~50~ = 26 nM, h = 1.5). Shown are means and standard errors for two independent experiments using cells from PID251. (**B**) The number of live infected cells normalized by the maximum number of live infected cells in coculture infection as a function of EFV for the K103N mutant. Black line represents best-fit model for the effect of EFV on coculture infection according to [Equation (3)](#equ3){ref-type="disp-formula"}, with *d* values calculated based on the cell-free infection data for the K103N mutant, and the mean number of HIV DNA copies in the absence of drug determined for L100I. The fits recapitulated the experimental results when *r* = 0.91 and *q* = 0.15. Shown are means and standard errors for three independent experiments. There were sufficient lymph node cells from PID251 for two of the three experiments, and the third experiment was performed with lymph node cells from PID274.](elife-30134-fig6){#fig6}

To examine if the observed peak in live cells may be due to EFV alone, we measured cell viability in lymph node cells from one of the study participants used in the above experiment as a function of EFV without infection. No clear dependence on EFV in the absence of infection was detected ([Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}).

Discussion {#s3}
==========

The optimal virulence concept in ecology proposes that virulence needs to be balanced against host survival for optimal pathogen spread ([@bib4]; [@bib6]; [@bib26]; [@bib33]). At the cellular level, this implies that the number of successfully infected cells may increase when infection virulence is reduced. The current study is, to our knowledge, the first to address this question experimentally at the level of individual cells infected with HIV.

Using a model where cells are infected and die in a probabilistic way, we found that there were two possible outcomes of partially inhibiting infection. In the case where cells were infected by single infection attempts, inhibition always led to a decline in the number of live infected cells, since inhibition reduced the number of infections per cell from one to zero. In contrast, in the case of multiple infection attempts per cell, the possibility existed that inhibition reduced the number of integrating HIV DNA copies, without extinguishing infection of the cell completely. If each HIV DNA copy increases the probability of cell death, reducing the number of HIV DNA copies without eliminating infection should lead to an increased probability of infected cell survival. This would consequently lead to an increase in the number of live infected cells.

We investigated the outcome of partial inhibition of infection in both a cell line and primary lymph node cells. In both systems, we observed that there was a peak in live infected cell number at intermediate inhibitor concentrations. This correlated to a decreased number of viral DNA copies per cell. Further increasing inhibitor concentration led to a decline in live infected cell numbers, and infecting with EFV resistant mutants shifted the peak in live infected number to higher EFV concentrations. Our model as described by [Equation (3)](#equ3){ref-type="disp-formula"} reproduced the essential behaviour of the experimental results. Construction of the model assumed independence of productive infection and cell death. However, as shown in the Appendix 1, an equivalent model can be constructed assuming a dependence of cell death on infection. Neither model accurately captures infection dynamics at high-drug concentrations, away from the infection optimum. In this range, where the number of infection attempts per cell is much lower than 1, infection declined more slowly with drug than predicted. The model can be further refined using a distribution for the number of DNA copies per cell. Moreover, the probability of death per HIV DNA copy we denote *q* may be dependent on how many infection attempts preceded the current infection attempt, and the model can be improved by measuring this dependence.

Physiologically, an infection optimum in the face of an antiretroviral drug may be important in HIV infection of lymph node cells and may be less pronounced in cells from peripheral blood. We used EFV in our study since it is a common component of first line antiretroviral therapy, with frequent drug resistance mutations. However, the infection optimum we describe should occur with other classes of antiretroviral drugs, since all drugs should decrease the multiplicity of infection between cells. In terms of modeling, a future therapy component such as the integrase inhibitor dolutegravir would exert its effect on *r* and not *λ* in our model. However, the effect is symmetrical since *e^-(λ/d)r^ = e^-λ(r/d)^*. The more complex outcome of partial inhibition of infection should also be considered in other infections where multiple pathogens infect one cell and host cell death is a possible outcome ([@bib41]).

These observations reinforce previous results showing that successful completion of reverse transcription leads to cellular cytotoxicity. In addition to HIV cytotoxicity caused by viral integrations through the mechanism of double strand breaks ([@bib11]), other mechanisms of HIV-induced death are also present, including IFI16-dependent innate immune system sensing of abortive reverse transcripts following non-productive infection of resting T cells ([@bib19]; [@bib43]). The experiments presented here reflect the effect of partial inhibition on productive infection of HIV target cells, which mostly consist of activated T-cell subsets, not resting T cells. More complex models would be needed to decipher the effect of partial inhibition of HIV infection on resting T-cell numbers and the outcome of this in terms of available T-cell targets in future infection cycles.

This study may have implications for the establishment of viral reservoirs in the context of poorly controlled infections, infections with some degree of drug resistance, or infections where some replication may take place in the face of ART, since infected cell survival is a pre-requisite for long-term persistence. The clinical implications of an infection optimum in the presence of EFV with EFV-sensitive HIV strains are likely to be negligible, since the drug concentrations at which the infection optimum occurs are extremely low. However, for EFV-resistant HIV, the infection optimum shifts to the range of EFV concentrations observed in lymph nodes (\~100 nM) ([@bib24]), and can be expected to shift to even higher EFV concentrations with more resistant mutants. As EFV has a longer half-life than the other antiretroviral drugs co-formulated with it, it may be the only agent present in partially adherent individuals for substantial periods of time ([@bib62]). Therefore, partial inhibition of HIV infection with EFV may provide a surprising advantage to EFV resistant mutants, and may allow individuals failing therapy to better transmit drug resistant strains.

Materials and methods {#s4}
=====================

Ethical statement {#s4-1}
-----------------

Lymph nodes were obtained from the field of surgery of participants undergoing surgery for diagnostic purposes and/or complications of inflammatory lung disease. Informed consent was obtained from each participant, and the study protocol approved by the University of KwaZulu-Natal Institutional Review Board (approval BE024/09). Blood for PBMC was obtained from healthy blood donors under the same study protocol.

Inhibitors, viruses and cell lines {#s4-2}
----------------------------------

The following reagents were obtained through the AIDS Research and Reference Reagent Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health: the antiretroviral EFV; RevCEM cells from Y. Wu and J. Marsh; HIV molecular clone pNL4-3 from M. Martin; ACH-2 cells from T. Folks. Cell-free viruses were produced by transfection of HEK293 cells with pNL4-3 using TransIT-LT1 (Mirus, Madison, WI ) or Fugene HD (Roche, [Risch-Rotkreuz](https://www.google.co.za/search?q=Risch-Rotkreuz+Switzerland&stick=H4sIAAAAAAAAAOPgE-LUz9U3MI83zbJUAjPTynMKC7S0spOt9POL0hPzMqsSSzLz81A4VhmpiSmFpYlFJalFxQCcivuGRAAAAA&sa=X&ved=0ahUKEwi80YOXwqXaAhUsKMAKHfWWCWsQmxMI2wEoATAT), [Switzerland](https://www.google.co.za/search?q=Risch-Rotkreuz+Switzerland&stick=H4sIAAAAAAAAAOPgE-LUz9U3MI83zbJUAjPTynMKC7S0spOt9POL0hPzMqsSSzLz81A4VhmpiSmFpYlFJalFxQCcivuGRAAAAA&sa=X&ved=0ahUKEwi08cmcvKXaAhUqIcAKHZpjA70QmxMI2wEoATAT)) transfection reagents. Virus containing supernatant was harvested after 2 days of incubation and filtered through a 0.45 µm filter (Corning, New York, NY). b12 antibody was produced from transfecting HEK293 cells with a b12 expression plasmid (expressed under a CMV promoter on a pHAGE6 lentiviral plasmid backbone, gift from A. Balazs), followed by harvesting of cell supernatant and purification at the California Institute of Technology protein expression core. The number of virus genomes in viral stocks was determined using the RealTime HIV-1 viral load test (Abbott Diagnostics, Santa Clara, CA). For *r* and *q* measurement, 0.45 µm filtered cell-free supernatants from infected RevCEM cells were used, to include any secreted factors which may modulate cell-death. The L100I and K103N mutants were evolved by serial passages of wild-type NL4-3 in RevCEM cells in the presence of 20 nM EFV. After 16 days of selection, the reverse transcriptase gene was cloned from the proviral DNA and the mutant reverse transcriptase gene was inserted into the NL4-3 molecular clone. RevCEM clones E7 and G2 used in this study were generated as previously described ([@bib7]). Briefly, the E7 clone was generated by subcloning RevCEM cells at single-cell density. Surviving clones were subdivided into replicate plates. One of the plates was screened for the fraction of GFP expressing cells upon HIV infection using microscopy, and the clone with the highest fraction of GFP-positive cells was selected. To generate the G2 clone, E7 cells were stably infected with the mCherry gene under the EF-1α promoter on a pHAGE2-based lentiviral vector (gift from A. Balazs), subcloned, and screened for \>99% mCherry-positive cells. All cell lines not authenticated, and mycoplasma negative. Cell culture and experiments were performed in complete RPMI 1640 medium supplemented with L-Glutamine, sodium pyruvate, HEPES, non-essential amino acids (Lonza, [Basel](https://www.google.co.za/search?q=Basel+Switzerland&stick=H4sIAAAAAAAAAOPgE-LSz9U3MCqrKjQyV-IAsQ2zTdK0tLKTrfTzi9IT8zKrEksy8_NQOFYZqYkphaWJRSWpRcUABHbPFEQAAAA&sa=X&ved=0ahUKEwiwv4y4wqXaAhXLDcAKHUVFD1IQmxMIswEoATAT), [Switzerland](https://www.google.co.za/search?q=Basel+Switzerland&stick=H4sIAAAAAAAAAOPgE-LSz9U3MCqrKjQyV-IAsQ2zTdK0tLKTrfTzi9IT8zKrEksy8_NQOFYZqYkphaWJRSWpRcUABHbPFEQAAAA&sa=X&ved=0ahUKEwjM7uXQvqXaAhUUesAKHZhrCYYQmxMIswEoATAT)), and 10% heat-inactivated FBS (GE Healthcare Bio-Sciences, Pittsburgh, PA).

Primary cells {#s4-3}
-------------

Lymph node cells were obtained by mechanical separation of lymph nodes and frozen at 5 × 10^6^ cells/ml in a solution of 90% FBS and 10% DMSO with 2.5 μg/ml Amphotericin B (Lonza). Cells were stored in liquid nitrogen until use, then thawed and resuspended at 10^6^ cells/ml in complete RPMI 1640 medium supplemented with L-Glutamine, sodium pyruvate, HEPES, non-essential amino acids (Lonza), 10% heat-inactivated FBS (Hyclone), and IL-2 at 5 ng/ml (PeproTech). Phytohemagglutinin at 10 µg/ml (Sigma-Aldrich, St Louis, MO) was added to activate cells. PBMCs were isolated by density gradient centrifugation using Histopaque 1077 (Sigma-Aldrich) and cultured at 10^6^ cells/ml in complete RPMI 1640 medium supplemented with L-Glutamine, sodium pyruvate, HEPES, non-essential amino acids (Lonza), 10% heat-inactivated FBS (GE Healthcare Bio-Sciences, Pittsburgh, PA), and IL-2 at 5 ng/ml (PeproTech, Rocky Hill, NJ). Phytohemagglutinin at 10 µg/ml (Sigma-Aldrich) was added to activate cells. For both primary cell types, donor cells for coculture infection were cultured for one day then infected by cell-free virus, while target cells were cultured for three days and infected with either cell-free HIV or infected donor cells.

Subcloning of ACH-2 cells {#s4-4}
-------------------------

Cells from the parental ACH-2 cell line were diluted to 10 cells/ml in conditioned medium, with conditioned medium generated by culturing ACH-2 cells to 10^6^ cells/ml, then filtering through a 0.22 µm filter (Corning). 25 μl of the diluted cell suspension was then distributed to each well of a Greiner μClear 384-well plate (mean of 0.5 cells per well). Clones were cultured for 3 weeks, where each week an additional 25 μl of conditioned medium was added to each well. Clones were detected in 5% of wells and two clones, designated D6 and C3, were randomly chosen and further expanded.

Infection {#s4-5}
---------

For a cell-free infection of RevCEM clones, PBMC and lymph node cells, 10^6^ cells/ml were infected with 2 × 10^8^ NL4-3 viral copies/ml (\~20ng p24 equivalent) for 2 days. For coculture infection, infected cells from the cell-free infection were used as the donors and cocultured with 10^6^ cells/ml target cells. For RevCEM clones, 2% infected donor cells were added to uninfected targets and cocultured for 2 days in tissue culture experiments, and 20% infected donor cells were added to uninfected targets and cocultured for 2 days for time-lapse experiments. For lymph node cells and PBMCs, a ratio of 1:4 donor to targets cells was used. Infection was over 2 days in PBMC infection and for 4 days for infection of lymph node cells.

Staining and flow cytometry {#s4-6}
---------------------------

To determine the number of live infected cells in reporter cell line experiments, E7 RevCEM reporter cells were infected as above used as donor cells. Prior to co-incubation with target cells, donor cells were stained with CellTrace Far Red (CTFR, Thermo Fisher Scientific, [Waltham](https://www.google.co.za/search?q=Waltham+Massachusetts&stick=H4sIAAAAAAAAAOPgE-LSz9U3MCooMTBJU-IAsTOqjE21tLKTrfTzi9IT8zKrEksy8_NQOFYZqYkphaWJRSWpRcUAAxikqkQAAAA&sa=X&ved=0ahUKEwja9p6Tv6XaAhXmB8AKHbk5C9cQmxMI0gEoATAP), MA) at 1 µM and washed according to manufacturer's instructions. The G2 mCherry-positive reporter cells were used as infection targets, and cocultured with 2% infected donor cells for 2 days. The coculture infection was pulsed with 100 ng/ml DAPI (Sigma-Aldrich) immediately before flow cytometry and the number of live infected targets cells was determined by the number of DAPI negative, CTFR negative and mCherry and GFP double positive cells on a FACSAria Fusion machine (BD Biosciences, Sparks, MD) using the 355, 488 and 633 nm laser lines. For cell-free infections where fewer fluorescence channels were used, a pulse of 300 nM of the far-red live cell impermeable dye DRAQ7 (Biolegend, San Diego, CA) immediately before flow cytometry was substituted for DAPI, and live infected cells detected as the number of DRAQ7-negative, GFP-positive cells on a FACSCaliber machine using 488 and 633 nm laser lines. Lymph node cells were resuspended in 1 ml of phosphate buffered saline (PBS) and stained at a 1:1000 dilution of the eFlour660 dye (Thermo Fisher Scientific) according to the manufacturer's instructions. Cells were then fixed and permeabilized using the BD Cytofix/Cytoperm Fixation/Permeabilization kit (BD Biosciences) according to the manufacturer's instructions. Cells were then stained with anti-p24 FITC conjugated antibody (KC57, Beckman Coulter, Brea, CA). Live infected lymph node cells were detected as the number of eFluor660-negative, p24-positive cells. Cells were acquired with a FACSAriaIII or FACSCaliber machine (BD Biosciences) using 488 and 633 nm laser lines. Results were analysed with FlowJo 10.0.8 software. For single-cell sorting to detect the number of HIV DNA copies per cell, cells were single-cell sorted using 85 micron nozzle in a FACSAriaIII machine. GFP-positive, DRAQ7-negative RevCEM clones were sorted 1 day post-infection into 96 well plates (Biorad, [Hercules](https://www.google.co.za/search?biw=1920&bih=925&q=Hercules+California&stick=H4sIAAAAAAAAAOPgE-LSz9U3MC4wzDVPUeIAsQsrCwu1tLKTrfTzi9IT8zKrEksy8_NQOFYZqYkphaWJRSWpRcUALCJywkQAAAA&sa=X&ved=0ahUKEwis1qy0wKXaAhVDKcAKHa_jAFMQmxMI0wEoATAS), CA) containing 30 µl lysis buffer (2.5 µl 0.1M Dithiothreitol, 5 µl 5% NP40 and 22.5 µl molecular biology grade water \[[@bib39]\]). For experiments to determine the number of HIV DNA copies to measure *r* and *q*, the DRAQ7-negative subset was sorted. Fixed, p24-positive, eFluor660-negative lymph node cells were single-cell sorted two days post-infection into 96-well plates containing 5 µl of PKD buffer (Qiagen, [Hilden](https://www.google.co.za/search?q=Hilden+Germany&stick=H4sIAAAAAAAAAOPgE-LUz9U3sDQ2z7JQAjON401yk7S0spOt9POL0hPzMqsSSzLz81A4VhmpiSmFpYlFJalFxQBsGJzXRAAAAA&sa=X&ved=0ahUKEwjv5_yUxKXaAhVQFMAKHS6lAI4QmxMI9gEoATAQ), [Germany](https://www.google.co.za/search?biw=1920&bih=925&q=Hilden+Germany&stick=H4sIAAAAAAAAAOPgE-LUz9U3sDQ2z7JQAjON401yk7S0spOt9POL0hPzMqsSSzLz81A4VhmpiSmFpYlFJalFxQBsGJzXRAAAAA&sa=X&ved=0ahUKEwil0p3FwKXaAhVGLMAKHW5NC3oQmxMI7gEoATAQ)) with 1:16 proteinase K solution (Qiagen) ([@bib64]). Sorted plates were snap frozen and kept at −80°C until ready for PCR. For analysis by flow cytometry, a minimum of 50,000 cells were collected per data point.

Time-lapse microscopy and image analysis {#s4-7}
----------------------------------------

For imaging infection by time-lapse microscopy, cell density was reduced to 5 × 10^4^ cells/ml and cells were attached to ploy-l-lysine (Sigma-Aldrich) coated optical six-well plates (MatTek, **Ashland, MA**). Infections with and without EFV were imaged in tandem using a Metamorph-controlled Nikon TiE motorized microscope with a Yokogawa spinning disk with a 20x, 0.75 NA phase objective in a biosafety level three facility. Excitation sources were 488 (GFP) and 561 (mCherry) laser lines and emission was detected through a Semrock Brightline quad band 440--40/521--21/607-34/700-45 nm filter. Images were captured using an 888 EMCCD camera (Andor, Belfast, UK). Temperature (37°C), humidity and CO~2~ (5%) were controlled using an environmental chamber (OKO Labs, Naples, Italy). Fields of view were captured every 20 min. To facilitate automated image analysis of time-lapse experiment data, mCherry expressing G2 clone cells were used as targets and E7 clone cells used as infected donors. The number of live cells was measured as the number of cells expressing mCherry since intracellular mCherry protein is soluble and hence lost upon cell death when cellular membrane integrity is compromised. The number of live infected cells was measured as the number of cells expressing both mCherry and GFP. Three independent experiments were performed. Movies were analyzed using custom code developed with the Matlab R2014a Image Analysis Toolbox. Images in the mCherry channel were thresholded and the imfindcircle function used to detect round objects within the cell radius range. Cell centers were found. GFP signal underwent the same binary thresholding. The number of mCherry-positive 16 pixel^2^ squares around the cell centers was used as the as the number of total target cells at each time-point, and the number of squares double positive for fluorescence in the GFP channel was used as the number of infected target cells.

Determination of HIV DNA copy number in individual cells {#s4-8}
--------------------------------------------------------

96-well plates of cells previously sorted at 1 cell per well were thawed at room temperature and spun down. Fixed cells were de-crosslinked by incubating in a thermocycler at 56°C for 1 hr. The lysate from each well was split equally over 10 wells (2.5 µl each well after correction for evaporation) for E7 RevCEM or four wells (6.8 µl each well after correction for evaporation) for lymph nodes, containing 50 µl of Phusion hot start II DNA polymerase (New England Biolabs, [Ipswich](https://www.google.co.za/search?q=Ipswich+Massachusetts&stick=H4sIAAAAAAAAAOPgE-LSz9U3MDKvyMoyV-IEsQ1zzQsqtbSyk63084vSE_MyqxJLMvPzUDhWGamJKYWliUUlqUXFAHZQROBFAAAA&sa=X&ved=0ahUKEwjPuuW5waXaAhWOa8AKHfBkB6sQmxMIxgEoATAS), MA) PCR reaction mix (10 µl 5X Phusion HF buffer, 1 µl dNTPs, 2.5 µl of the forward primer, 2.5 µl of the reverse primer, 0.5 µl Phusion hot start II DNA polymerase, 2.5 µl of DMSO and molecular biology grade water to 50 µl reaction volume). Two rounds of PCR were performed. The first round reaction amplified a 700 bp region of the reverse transcriptase gene using the forward primer 5' CCTACACCTGTCAACATAATTGGAAG 3' and reverse primer 5' GAATGGAGGTTCTTTCTGATG 3'. Cycling program was 98°C for 30 s, then 34 cycles of 98°C for 10 s, 63°C for 30 s and 72°C for 15 s with a final extension of 72°C for 5 min. 1 µl of the first round product was then transferred into a PCR mix as above, with nested second round primers (forward 5' TAAAAGCATTAGTAGAAATTTGTACAGA 3', reverse 5' GGTAAATCCCCACCTCAACAGATG 3'). The second round PCR amplified a 550 bp product which was then visualized on a 1% agarose gel. PCR reactions were found to work best if sorted plates were thawed no more than once, and plates which underwent repeated freeze-thaw cycles showed poor amplification.

Correction of raw number of detected DNA copies for detection sensitivity {#s4-9}
-------------------------------------------------------------------------

A stochastic simulation in Matlab was used to generate a distribution for the number of positive wells per cell for each mean number of DNA copies per cell *λ*. The probability for a DNA copy to be present within a given well and be detected was set as *σ/w*, where *σ* was the detection sensitivity calculated as the number of ACH-2 with detectable integrations divided by the total number of ACH-2 cells assayed (38/166, *σ* = 0.23), and *w* was the number of wells. A random number *m* representing DNA copies per cell from a Poisson distribution with a mean *λ* was drawn, and a vector *R* of *m* random numbers from a uniform distribution was generated. If there existed an element R~i~ of the vector with a value between 0 and *σ/w*, the first well was occupied. If an element existed with a value between *σ/w+γ* and 2(*σ/w),* where *γ* \<\<1, the second well was occupied, and if between (*σ/w+γ)(n-1)* and n(*σ/w),* the *nth* well was occupied. The sum of wells occupied at least once was determined, and the process repeated *j* times for each *λ*, where *j* was the number of cells in the experimental data. A least squares fit was performed to select *λ* which best fit the experimental results across well frequencies, and mean and standard deviation for *λ* was derived by repeating the simulation 10 times.

Fit of the EFV response for single infections using IC~50~ and Hill coefficient {#s4-10}
-------------------------------------------------------------------------------

To obtain *d*, we normalized [Equation (2)](#equ2){ref-type="disp-formula"} by the fraction of infected cells in the absence of drug ([@bib59]) to obtain *Tx =* (infected targets with EFV)/ (infected targets no EFV)= *((1- (1 r)^λ/d^) (1-q)^λ/d^)/ ((1- (1 r)^λ^) (1-q)^λ^)*. We approximate the result at small *r, q* to *Tx =* (*1- e^-rλ/d^) e^-qλ/d^/* (*1- e^-rλ^) e^-qλ^=eq^qλ(1-1/d)^ ((1- e^-rλ/d^) / (1- e^-rλ^)).* Expanding the exponentials we obtain *Tx = (1 + qλ(1--1/d))* ((*-rλ/d)/-rλ) = (1 + qλ(1--1/d))(1/d).* We note that at *λ \<1, qλ(1--1/d)\<\<1,* and hence *Tx ≅ 1/d. Tx* was measured from the experiments to obtain *d* values at the EFV concentrations used for cell-free infection, where *λ \< 1*. To obtain a fit of *d* as a function of the concentration of drug that gives half-maximal inhibition (IC~50~) and Hill coefficient (h) for EFV, we used the relation for the fraction cells remaining infected in the face of drug ([@bib9]), whose definition is equivalent to *Tx* at *λ \< 1*:$$\frac{1}{d} = 1 - \  = 1 - \frac{\left\lbrack {EFV} \right\rbrack^{h}}{\left\lbrack {EFV} \right\rbrack^{h} + IC_{50}^{h}}.$$

Measurement of *r* {#s4-11}
------------------

Cell-free supernatant used in infection was derived as follows: 10^6^ cells/ml were infected with 2 × 10^8^ NL4-3 viral copies/ml (\~20ng p24 equivalent) for 2 days. Thereafter 0.2% of the infected cells from the cell-free infection were added to 10^6^ cells/ml target cells. The infected supernatant from the coculture 2 days post-infection was filtered using a 0.45 µm filter (Corning) and added to cells at a 1:8 dilution, where the dilution was calibrated to result in non-saturating infection in terms of GFP expression. A fraction of the cells were sorted into lysis buffer at one cell per well 1 day post infection, split over four wells, and PCR performed as described above to determine HIV copy number per cell. The remaining cells from the same infection were used to determine frequency of DRAQ-7-negative, GFP-positive cells 2 days post-infection using flow cytometry.

Measurement of *q* {#s4-12}
------------------

Cell-free supernatant used in infection was derived as for *r*, except that 1 day before harvesting of the viral supernatant from infected cells, infected cells were washed twice with PBS and serum-free growth medium added. At the same time, the target cells for the infection were washed twice with PBS and serum-free growth medium added. Cells were split into two wells, and EFV to a final concentration of 40 nM was added to one of the wells. Supernatant was harvested and filtered as described for *r*, and added to cells at a 1:2 dilution. A fraction of the cells were sorted into lysis buffer at one cell per well 1 day post-infection, split over four wells, and PCR performed as described above to determine HIV copy number per cell. The remaining cells from the same infection were used to determine the frequency of live and dead cells two days post-infection. The concentration of live cells was measured using the TC20^TM^ automated cell counter (Bio-Rad) with trypan blue staining (Lonza).
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I Derivation of infection model assuming independence of infection and cell death {#s7-1}
---------------------------------------------------------------------------------

We consider a model of infection where is the probability of one HIV DNA copy to successfully infect the cell and is the probability of the cell to die as a result of the infection attempt. The probability of being infected when virions enter the cell is:$${P_{n} = {{({1 - {({1 - r})}^{n}})}{({1 - q})}^{n}}}.$$

If the number of infection attempts, $n$, is Poisson distributed with mean $\lambda$, the fraction of cells that are productively infected is:$$\begin{matrix}
P_{\lambda} & {= e^{- \lambda}\sum\limits_{n}\frac{\lambda^{n}}{n!}P_{n} = e^{- \lambda}\sum\limits_{n}\frac{\lambda^{n}}{n!}(1 - (1 - r)^{n})(1 - q)^{n}} \\
 & {= e^{- \lambda}\sum\limits_{n}\frac{(\lambda(1 - q))^{n}}{n!} - \frac{(\lambda(1 - r)(1 - q))^{n}}{n!}} \\
 & {= e^{- \lambda q}(1 - e^{- \lambda r(1 - q)}).} \\
\end{matrix}$$

We introduce a drug strength value $d$, where $d = 1$ in the absence of drug and $d > 1$ in the presence of drug. In the presence of drug, $\lambda$ is decreased to $\lambda/d$. The drug therefore tunes $\lambda$. The probability of a cell to be infected and live given drug strength $d$ is therefore:$${P_{\lambda/d} = {e^{- {{\lambda q}/d}}{({1 - e^{- {{\lambda r{({1 - q})}}/d}}})}}}.$$

Experimentally, we measure $P_{\lambda}$, the number of infected cells, and $L_{\lambda}$, the number of live cells remaining two days post-infection for the cell line.

Assuming a Poisson distribution of the number of infection attempts, the probability of being productively infected is$${{P_{\lambda} = \left. {1 - e^{- {\lambda r}}}\quad\Rightarrow \right.}\quad{r = {- \frac{\log{({1 - P_{\lambda}})}}{\lambda}}}}.$$

Similarly, the probability of a cell to live is$${{L_{\lambda} = \left. e^{- {\lambda q}}\quad\Rightarrow \right.}\quad{q = {- \frac{\log{(L_{\lambda})}}{\lambda}}}}.$$

II Derivation of infection model assuming dependence of infection and cell death {#s7-2}
--------------------------------------------------------------------------------

Cellular infection and death may be the result of independent processes. For example, cell death may be a programmed response to DNA damage induced by the infection attempt and therefore may occur regardless of whether or not the cell is successfully infected. Infection and death may also be dependent. One example of dependence is the cytotoxicity mediated by expressed viral proteins after integration into the host genome.

In this case, the probability of productive infection and survival of the cell given $n$ attempts is$$P_{n} = {\sum\limits_{m = 1}^{n}{\begin{pmatrix}
n \\
m \\
\end{pmatrix}{({r^{\prime}{({1 - q^{\prime}})}})}^{m}{({1 - r^{\prime}})}^{n - m}}}$$

Here, $r^{\prime}$ and $q^{\prime}$ are the probabilities for infection and death respectively. Their relationship to the experimentally measured $r$ and $q$ are discussed in the next section. $\left\lbrack {r^{\prime}{({1 - q^{\prime}})}} \right\rbrack^{m}$ is the probability that $m$ infection attempts are successful and none of the attempts triggers cell death, while ${({1 - r^{\prime}})}^{n - m}$ accounts for $n - m$ unsuccessful infections. To obtain the total probability of productive infection without cell death given $n$ attempts, we sum over all cases with $m^{\prime} \geq 1$ sucessful infections.

Realizing that:$$\begin{matrix}
{\sum\limits_{m = 1}^{n}{(\frac{n}{m})}(r^{\prime}(1 - q^{\prime}))^{m}(1 - r^{\prime})^{n - m}} & {= \sum\limits_{m = 0}^{n}{(\frac{n}{m})}(r(1 - q))^{m}(1 - r^{\prime})^{n - m} - (1 - r^{\prime})^{n}} \\
 & {= (r^{\prime}(1 - q^{\prime}) + (1 - r^{\prime}))^{n} - (1 - r^{\prime})^{n}\ ,} \\
\end{matrix}$$we can simplify the above to:$${P_{n} = {{({{r^{\prime}{({1 - q^{\prime}})}} + {({1 - r^{\prime}})}})}^{n} - {({1 - r^{\prime}})}^{n}} = {{({1 - {r^{\prime}q^{\prime}}})}^{n} - {({1 - r^{\prime}})}^{n}}}.$$

Averaging this over a Poisson distribution with mean$\lambda$, we find:$${{e^{- \lambda}{\sum\limits_{n}{\frac{\lambda^{n}}{n!}P_{n}}}} = {e^{- \lambda}{\sum\limits_{n}{\frac{\lambda^{n}}{n!}{({{({1 - {r^{\prime}q^{\prime}}})}^{n} - {({1 - r^{\prime}})}^{n}})}}}} = {e^{- {\lambda r^{\prime}q^{\prime}}} - e^{- {\lambda r^{\prime}}}}}.$$

III Equivalence of the two models {#s7-3}
---------------------------------

The two models predict same dependence on $\lambda$ (the difference of two exponentials) but the parameters $r,q$ and $r^{\prime},q^{\prime}$ play slightly different roles. The models are the same if:$${{{r^{\prime}q^{\prime}} = {q\quad{and}}}\quad{r^{\prime} = {{r{({1 - q})}} + q}}}.$$

Hence the two models are a re-parametrization of the same process. The experimental measurement of $r$ and $q$, as described in the main manuscript, consists of estimating $r$ as the fraction of infected cells when the fraction of dead cells is low due to a low number of measured DNA copies per cell. The death rate $q$ is derived by measuring the number of live cells remaining when the number of HIV DNA copies per cell is known. If the probability of death is dependent on infection, then death is only of infected cells and is a product of the probability to be infected and die ($r^{\prime}q^{\prime}$). Likewise, the underlying probability of infection $r^{\prime}$ will account for the fraction dead cells ($q$) and any cells which are infected but not dead ($r{({1 - q})}$).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Incomplete inhibition of HIV infection results in more HIV infected lymph node cells by reducing cell death\" for consideration by *eLife*. Your article has been evaluated by Wenhui Li (Senior Editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Jackson et al. mathematically predicted and experimentally demonstrated that in lymph node cells, intermediate antiviral (anti-HIV) drug concentrations can allow infected cells to live longer by reducing multiplicity of infection. Thus, intermediate drug concentration can presumably facilitate the persistence of HIV. The result is interesting and can have clinical implications.

Reviewer \#1\'s concern is quite substantial. Other reviewers agreed to this concern. \"I strongly believe that infection probability r and death probability q should be measured experimentally. This is to eliminate fitting parameters and to ensure quality of the model.\"

Comments from Reviewers 2 and 3 are attached.

*Reviewer \#2:*

The studies presented by Sigal et al. examine the interrelationship between cell death and the number of DNA copies of HIV that are detected per individual infected cell. Previous studies from a number of groups, including Sigal\'s, have indicated that cell-to-cell infection leads to infected cells with a higher number of integrated proviruses. The single cell PCR data provided by Sigal et al. support a hypothesis that the cell-to-cell infection not only leads to higher copy number of proviruses, but also generally leads to more rapid cell death. Using drugs or antibodies at low levels that do not fully inhibit infection, they found that low levels of inhibition paradoxically can give rise to a larger number of surviving infected cells. They also appear to find lower rates of cell death under conditions of partial inhibition. The studies are generally well conceived, and the results generally support the conclusions. The overall quality of the data could be improved by showing additional controls and increasing the numbers of cells analyzed to enhance the confidence in the copy number estimates. On the cell death front, it would be helpful for their hypothesis to show a time course with the cell death depicted over time. Lastly, an important detail not mentioned, is whether the use of lymph node cells is critical or not for the phenotypes that they describe. The study may have implications for the establishment of viral reservoirs in the context of poorly controlled infection or infections with some degree of drug resistance.

1\) The authors use the ACH2 cell line to test the ability of their assay to detect single copy integrations. Why do they only spread each cell over 4 wells in control studies as opposed to the 10 wells used in their experimental studies? The rationale for using different dilution schemes should be explained. A comparison of the efficiency of PCR at the different dilutions would also be informative.

The ACH2 cell line yields fewer than 1 copy per cell, which may be a limitation of the PCR assay, but also could be reflective of heterogeneity in a cell line that is assumed to be clonal and a uniform karyotype. It is not described how recently the ACH2 cell line that they are using has been cloned. Repeating the ACH2 studies with a subclone would be beneficial.

Figure 2 would be more informative if it showed the results of both cell-free virus infection versus coculture infection. The numbers of cells analyzed in Figure 2C (n=34) does not appear sufficient to provide a robust sense of the distribution of the DNAs in the infected cells. Is this a bimodal distribution? Histogram comparison of cell-free should also be used for comparison.

2\) Figure 4.

What happens with partial antibody inhibition of cell-free infection? These studies should be performed with infection from cell-free virus. To further test their hypothesis partial inhibition of cell-free infection should only decrease infected cells.

3\) Figure 5.

As controls for cell death measurements, the viability of the uninfected control lymph node cells, treated and untreated, should also be illustrated. In the literature lymph node cells (mostly tonsilar) are very prone to cell death, and it is important to understand to what extent they are measuring virus-induced cell death. In addition, a time course of the cell death observed in the infections may would also be helpful to evaluate their hypothesis that the increase of infected cells in the partially treated cells is due to increased infected cell survival -- i.e. decreased death.

4\) Are the phenotypes described in the primary lymph node cells also observed for peripheral blood lymphocytes? Or are there differences between the peripheral blood versus the lymph node T cells.

*Reviewer \#3:*

This is an interesting and worthwhile paper that examines the effects of incomplete inhibition of HIV infection with reverse transcription inhibitors. The experimental results presented are in accordance with model predictions. However, the presentation of the model should be improved as detailed below. Also, I found the labeling and numbering of the supplemental figures confusing. I have no substantial concerns and this the paper should be published after minor revision.

1\) The terms and concepts in the paper are not clearly defined. In the first paragraph of the Results, you mention each donor to target transmission. It is not clear what a transmission is. Does it refer to viral entry of either a free virus or a virus (or genome) by cell-to-cell transmission? It needs to be defined. Second define what you mean by infection. Does a cell have to produce virus to be considered infected? Does the virus have to integrate or is it sufficient to simply reverse transcribe? Is a latently infected cell an infected cell in your model? Also, when you say drug therapy increases the number of live infected cells do you mean live productively infected cells, live HIV DNA^+^ cells, etc.

2\) The assumption that all transmissions have equal probabilities to infect target cells seems to ignore the possibility that some virions carry defective genomes while others do not. This does not seem realistic. In your experimental system is the ratio of HIV RNA to TCID50 close to one so you can ignore defective particles?

3\) You assume productive infection and death are independent events. While the events may be independent the probability of death is certainly not independent of whether a cell is productively infected or not. Further the probability of death is time dependent. The probability a cell dies one hour after viral entry (infection?) is clearly quite different than the probability it dies days after infection. You may want to define q as the probability a cell has died by time t after infection and the same for Pλλ where t is 2 days or 4 days for your various experiments.

4\) Results, second paragraph. You claim antiretroviral drugs reduce the number of infecting virions. This implies that by infecting you must mean the virus reverse transcribes. In standard viral dynamic models the effects of ART are to reduce the infection probability, i.e., r in your model not λ. Thus it is important to clarify your definitions.

5\) You introduce the drug effect as a constant d in the second paragraph of the Results. Later in the paper you make reference to IC~50~ and Hill coefficients for the drug. These need to be tied together in an explicit manner. In viral dynamic modeling the effectiveness of a drug, epsilon, (eps) is introduced where eps=1 is a 100% effective drug, e.g. stops all reverse transcription, and where eps=0 means the drug has no effect. Then a pharmacodynamic model is used to relate eps with the drug concentration, C, e.g. eps= C\^n/(IC50\^n + C\^n). Thus rather than λ/d you could model the drug effect by (1-eps)λ and use the above formula to link the effect to drug concentration. See for example, Canini and Perelson, 2014. Equation 3 in your manuscript accomplished the same, but the above seems more straightforward.

6\) Results, fourth paragraph. When you measure the number of reverse transcribed copies of viral DNA I assume you are measuring both integrated and unintegrated DNA -- please state this explicitly as later you seem to imply you are measuring integrated DNA, e.g. Results, sixth paragraph.

7\) The current work focuses only on reverse transcriptase inhibitors. Model therapy uses combination therapy including integrase inhibitors and protease inhibitors. Expanding the discussion of the clinical implications of this work to include combination therapy would be worthwhile.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for submitting your article \"Incomplete inhibition of HIV infection results in more HIV infected lymph node cells by reducing cell death\" for consideration by *eLife*. Your article has been favorably evaluated by Wenhui Li (Senior Editor) and three reviewers, one of whom, Wenying Shou (Reviewer \#1), is a member of our Board of Reviewing Editors. The following individual involved in review of your submission has agreed to reveal his identity: Alan Perelson (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We want you to address the following comments. Note that we are not asking you to do further experiments. For the sake of record-keeping, we are enclosing all comments.

*Reviewer \#1:*

I am satisfied with their measurements.

In general, I suggest breaking up long sentences (especially the one in Abstract, also the end of the third paragraph in the Introduction) for readability. Sentences that last more than three lines are generally more difficult to read than shorter sentences.

*Reviewer \#2:*

The authors have very rigorously addressed the critiques by performing new experiments and modifying the text. The response to the reviews is particularly comprehensive and thorough. The resulting new data are supportive of the original model and hypothesis. The authors should be commended.

*Reviewer \#3:*

In this revised version on the paper the authors have clarified their definitions by incorporating a supplemental table and additional text describing their model. However, this clarification has raised the following issues that need to be resolved:

1\) As defined in the Results, λ is the number of infection attempts, where one attempt is measured as one HIV DNA copy. Thus, λ is an integer. The formula, Equation 1, makes sense when λ is an integer. However, what is determined experimentally is not the integer number of DNA copies but rather the mean number of copies per cell, which is not necessarily an integer. To make sense Equation 1 should be reformulated as a conditional probability of a cell being infected and alive given x attempts, call this P(I \| x). What I believe the authors want is the probability of a cell being infected and alive, which is then P(I) =Sum P(I \|x) (p(x)), where p(x) is the probability of having x infection attempts, and the sum is over all non-negative values of x. One could then assume, for example, that the number of attempts is Poisson distributed with mean λ. Then the resulting formula for P(I) would involve the mean value of the number of attempts. A better choice would be the empirical distribution that the authors measured. Note that what is actually measured is the number of infected cells that are alive at a certain time, i.e. P(I), and the mean number of attempts, what I called λ above.

2\) According to the model q should be independent of the number of attempts. Can this be tested by using different drug concentrations, which would vary the mean number of attempts? If you already have experimental data on this, then include them. Otherwise, just discuss it.

3\) In the original manuscript where Equation 1 was derived the authors assumed q was independent of r. In the second paragraph of the Results the authors say q is the probability of a cell to die post reverse transcription, which seems more sensible to me. Under the original assumption of q and r being independent, a cell in which the attempt was unsuccessful would have the same probability of dying as a cell in which reverse transcription succeeded. With q now defined as in the second paragraph of the Results, the fundamental formula given by Equation 1 may not be correct and deserves a more thorough discussion. I think the fundamental process being described is that at each attempt a cell is either infected with probability r, or not infected with probability 1-r. If it is infected, i.e. had a successful reverse transcription, then with probability q it remains alive and with probability 1-q it dies. Assume there are x attempts. Let z be the number of cells infected after x attempts. Then z is binomially distributed, i.e. z= Bin (x,r). Further, if we are interested in the number of cells infected and alive after x attempts, then P(I\|x) = Sum_z=1 to x (x choose r) r\^z (1-r)\^(x-z)(1-q)\^z, where the factor (1-q)\^z is the probability of a cell surviving after each of the z infections. Simplifying, P(I\|x) = \[r(1-q) + (1-r)\]\^x, which is not the same as Equation 1. The number of attempts, x, is again random and as above one can convert this conditional probability into P(I) by assuming a Poisson (or some other distribution such as the empirically measured one) for the number of attempts p(x).

4\) In Supplementary file 1 the authors say the way they measure the probability a cell is alive after λ attempts is by computing the concentration of cells alive with λ attempts divided by the concentration of cells alive with no transmissions. However, since the concentration of cells alive with no transmissions can approach zero as time goes on it is clear that this fraction need not be less than 1. Also, as noted above the authors need to use conditional probabilities and derive formulas that involve the mean number of attempts. I would suggest they compute the ratio of the probability a cell is infected to the probability a cell in not infected and alive, which is what they measure, and see if they can derive a formula for q.

10.7554/eLife.30134.040

Author response

> Reviewer \#1\'s concern is quite substantial. Other reviewers agreed to this concern. \"I strongly believe that infection probability r and death probability q should be measured experimentally. This is to eliminate fitting parameters and to ensure quality of the model.\"

In order to address this important point, we designed two sets of experiments, one set for measuring r and the other for q. The definition for r and q is now sharpened as suggested by reviewer 3 in Supplementary file 1 (as described in the response to reviewer 3 comments).

Our general approach was to use cell-free infection to avoid the high multiplicity of infection and broad distribution of HIV copy number observed in cell-to-cell spread. We then measured the fraction of live infected cells (P~λ~) or cell viability (L~λ~) post-infection. For each set of experiments we determined the number of infection attempts λ, which was measured as the number of total HIV DNA copies per cell, both integrated and unintegrated. This enabled us to calculate p and q (see below). For q, we compared infected cells to cells infected but treated with 40nM efavirenz, sufficient to reduce reverse transcription to negligible levels in cell-free infection (see Figure 2D). Hence we measured the effect on cell viability of infection from the reverse transcription step onward, as this is what is compared in all our experiments.

Two independent experiments were performed in the cell line per parameter, with each experiment including cell sorting followed by PCR to obtain λ. The specific approach for each parameter was as follows:

> Measurement of r (probability of infection per transmission)

1\) r was measured using cell-free infection followed by flow cytometry 2 days post-infection to determine frequency of live infected cells P~λ~, as measured by the fraction of live GFP positive cells normalized by the maximum fraction of cells which can become GFP positive upon infection in our system (70%).

2\) λ, the number of viral transmissions per cell, was defined as the average number of detected HIV DNA copies per cell both integrated and unintegrated (see response to reviewer 3 below), as detected by splitting a single cell over multiple wells and performing PCR for HIV DNA.

3\) Given that live cells were selected, r = 1-(1-P~λ~)^1/λ^

> Measurement of q (probability of cell death per transmission)

1\) The fraction of live cells remaining post-reverse transcription, defined as L~λ~ =\[live cells with infection\]/\[live cells when reverse transcription blocked\], was measured with cell-free infection by determining the concentration of live cells using cell counting with trypan blue exclusion. To prevent cell numbers changing due to cell division, proliferation was blocked by serum starvation.

2\) λ was defined and measured as with r.

3\) q = 1-L~λ~^1/λ^.

Results of experiments are shown in the new Figure 2---figure supplement 4.

The results are also summarized in Supplementary file 2.

We used the measured values to calculate P~λ~ using Equation 2. The results are presented in Figure 2E, green line.

The measured q value is higher than our fit (0.14 versus 0.08) and the r value lower (0.24 versus 0.40). However, the pattern of the peak is not strongly affected. What this demonstrates is that the measured r and q are in the correct range in the cell line system to explain the observed peak.

This result is now presented in the main text in the Results section:

"In order to determine whether the fitted *r* and *q* values were within a reasonable range, we measured these values experimentally. \[...\] The solution to Equation 2 using these values was very similar to the solution with the fitted values, indicating that the fitted values gave a reasonable approximation of the behavior of the system (Figure 2E, green dotted line)."

The methods to measure r and q are presented in the Materials and methods section:

"Measurement of *r*

Cell-free supernatant used in infection was derived as follows: 10^6^ cells/ml were infected with 2x10^8^ NL4-3 viral copies/ml (\~20ng p24 equivalent) for 2 days. \[...\] The remaining cells from the same infection were used to determine frequency of DRAQ-7 negative, GFP positive cells 2 days post-infection using flow cytometry."

"Measurement of *q*

Cell-free supernatant used in infection was derived as for *r*, except that one day before harvesting of the viral supernatant from infected cells, infected cells were washed twice with PBS and serum-free growth medium added. \[...\] The concentration of live cells was measured using the TC20^TM^ automated cell counter (Bio-Rad) with trypan blue staining (Lonza)."

To measure r and q in lymph node cells is not practical. This is because the infection is of a subset of lymph node cells (\~10%). Therefore, measurement of λ where most cells are uninfected would require months of running gels. Furthermore, it is very unlikely that we could measure q using the approach above, since a given frequency of cell death in the infectable cell subpopulation would be diluted to a much lower frequency over the whole cell population, and unlikely to be detected above the high background lymph node cell death.

> Comments from Reviewers 2 and 3 are attached.
>
> Reviewer \#2:
>
> \[...\] The overall quality of the data could be improved by showing additional controls and increasing the numbers of cells analyzed to enhance the confidence in the copy number estimates.

Additional controls were added as detailed in the replies to the reviewer's specific comments. The number of cells analyzed increased as follows:

For ACH-2 cells, in total an additional 95 cells were analyzed, bringing to total analyzed cells to 166. This is now shown in Figure 2---figure supplement 1.

For the cell line infected with cell-free virus, an additional 12 cells were analyzed, bringing the total analyzed cells to 30. For coculture infection, an additional 26 cells were added, bringing the total analyzed cells to 60. These results are presented in Figure 2C with cell-free data now included as an inset.

With the new results, the mean number of corrected HIV DNA copies per cell was 17.

> On the cell death front, it would be helpful for their hypothesis to show a time course with the cell death depicted over time.

We now include time-lapse microscopy data showing the depletion of target cells in the absence and presence of efavirenz. The experiments show the total number of live and live infected cells in the optical dish with no drug, and in the presence of efavirenz. These experiments were done before we finalized experimental conditions, so the input of wild type virus infected donor cells (20%) and the corresponding efavirenz concentrations (30nM) were higher. However, the data clearly shows that extensive death due to infection occurs in the absence of drug, and is prevented by efavirenz. The data is presented as Figure 2---figure supplement 5.

This is now described in the Results section:

"In order to investigate the dynamics of cell depletion due to cell-to-cell HIV spread and its modulation by addition of inhibitor, we performed time-lapse microscopy over a two day infection window. \[...\] The deterioration in live cell numbers was averted by the addition of EFV (Figure 2---figure supplement 5)."

The method used is described in the Materials and methods:

"Time-lapse microscopy and image analysis

For imaging infection by time-lapse microscopy, cell density was reduced to 5x10^4^ cells/ml and cells were attached to ploy-l-lysine (Σ-Aldrich) coated optical six well plates (MatTek). \[...\] The number of mCherry positive 16 pixel^2^ squares around the cell centers was used as the as the number of total target cells at each time-point, and the number of squares double positive for fluorescence in the GFP channel was used as the number of infected target cells."

> Lastly, an important detail not mentioned, is whether the use of lymph node cells is critical or not for the phenotypes that they describe.

In this study we concentrated on lymph nodes, which were reported to be sites of lower drug penetration as well as efficient HIV replication. However, we did try PBMCs, and observed no obvious fitness optimum, as reviewer 2 suggests may be a possibility since PBMCs are less prone to cell death relative to lymph node cells. The first set of 3 independent experiments using blood from one healthy donor showed a small peak at a very low EFV concentration. We then focused on the lower EFV concentration range but could not reproduce the peak in other donors. These results are presented as Figure 5---figure supplement 1.

It is described in the Results section:

"Peaks in the number of live infected cells in the face of drug may be specific to lymph node derived cells. Cell-to-cell infection of peripheral blood mononuclear cells (PBMC) with wild type HIV showed a slight peak at a very low EFV concentration in cells from one blood donor, which was not repeated in cells from two other donors (Figure 5---figure supplement 1)."

We add this observation to the Discussion:

"Physiologically, an infection optimum in the face of an antiretroviral drug may be important in lymph node cell HIV infection and may be less pronounced in infectable cells from peripheral blood."

> The study may have implications for the establishment of viral reservoirs in the context of poorly controlled infection or infections with some degree of drug resistance.

We thank the reviewer for this concise summary and add it to the Discussion:

"This study may have implications for the establishment of viral reservoirs in the context of poorly controlled infections, infections with some degree of drug resistance, or infections where some replication may take place in the face of ART, since infected cell survival is a pre-requisite for long term persistence."

> 1\) The authors use the ACH2 cell line to test the ability of their assay to detect single copy integrations. Why do they only spread each cell over 4 wells in control studies as opposed to the 10 wells used in their experimental studies? The rationale for using different dilution schemes should be explained. A comparison of the efficiency of PCR at the different dilutions would also be informative.

There is no reason for the difference except that we started with 10 well spreads in cell line coculture infections and realized that we can use less reagents to obtain the same data. We now state this in the Results section:

"Using fewer wells saved reagents without changing sensitivity, as demonstrated in the ACH-2 cell line (Figure 2---figure supplement 1C)."

We compared efficiency of HIV copy detection in ACH-2 cells between 4 and 10 well spreads and did not find a substantial difference, as the frequency in the 10-well split was 0.27 while the parental was 0.24. The data is presented in Figure 2---figure supplement 1,

We describe this in the Results section:

"Similar results were obtained when the ACH-2 cell line was subcloned or split over 10 wells (Figure 2---figure supplement 1C)."

> The ACH2 cell line yields fewer than 1 copy per cell, which may be a limitation of the PCR assay, but also could be reflective of heterogeneity in a cell line that is assumed to be clonal and a uniform karyotype. It is not described how recently the ACH2 cell line that they are using has been cloned. Repeating the ACH2 studies with a subclone would be beneficial.

We subcloned the ACH-2 cells as described in the Materials and methods:

"Subcloning of ACH-2 cells

Cells from the parental ACH-2 cell line were diluted to 10 cells/ml in conditioned medium, with conditioned medium generated by culturing ACH-2 cells to 10^6^ cells/ml, then filtering through a 0.22µm filter (Corning). \[...\] Clones were detected in 5% of wells and two clones, designated D6 and C3, were randomly chosen and further expanded."

We checked two subclones, with 56 cells measured in the first subclone and 24 in the second. Frequency of detection in each was 0.21, which we judged was not substantial relative to the parental line. We describe the results in Figure 2---figure supplement 1C above.

> Figure 2 would be more informative if it showed the results of both cell-free virus infection versus coculture infection. The numbers of cells analyzed in Figure 2C (n=34) does not appear sufficient to provide a robust sense of the distribution of the DNAs in the infected cells. Is this a bimodal distribution? Histogram comparison of cell-free should also be used for comparison.

We now include the cell-free distribution as an inset in Figure 2C. Frequency of HIV DNA copies was 0.23, as described in the response to general comment 3. We describe this in the Results section:

"We also detected the HIV copy number in 30 GFP positive cells infected by cell-free HIV. In this case, we detected either zero or one HIV copy per cell (Figure 2C inset). The frequency of single HIV DNA copies was 0.23, identical to the measured result in the ACH2 cell line."

We checked the fit of the distribution resulting from coculture infection, which we expanded to 60 analyzed cells. While a distribution with two means fit the data better, we could not rule out that this was due to added fit parameters since the fitted distribution itself did not show peaks. Most likely, this means that the peak at 5 raw copies and no cells at 6 copies is a chance event that gives an impression of bimodality. The results are presented in Figure 2---figure supplement 2.

These results are described in the Results section:

"We assayed 60 cells and obtained a wide distribution of viral DNA copies per cell, which ranged from 0 to 9 copies (Figure 2C). \[...\] The frequency of single HIV DNA copies was 0.23, identical to the measured result in the ACH-2 cell line."

> 2\) Figure 4.
>
> What happens with partial antibody inhibition of cell-free infection? These studies should be performed with infection from cell-free virus. To further test their hypothesis partial inhibition of cell-free infection should only decrease infected cells.

We now include the results for antibody inhibition of cell-free infection as Figure 4---figure supplement 1. As can be seen, antibody only decreases infected cells in cell-free infection.

This is described in the Results section:

"In contrast, cell-free infection in the face of b12 showed a sharp and monotonic drop in live infected cells for both wild type and mutant virus (Figure 4---figure supplement 1)."

> 3\) Figure 5.
>
> As controls for cell death measurements, the viability of the uninfected control lymph node cells, treated and untreated, should also be illustrated. In the literature lymph node cells (mostly tonsilar) are very prone to cell death, and it is important to understand to what extent they are measuring virus-induced cell death.

We measured cell death in uninfected lymph node cells, untreated and treated with efavirenz. We did not find that efavirenz alone results in a peak of live cells (Figure 6---figure supplement 3).

This is discussed in the Results section:

"To examine if the observed peak in live cells may be due to EFV alone, we measured cell viability in lymph node cells from one of the study participants used in the above experiment as a function of EFV without infection. No dependence on EFV in the absence of infection was detected (Figure 6---figure supplement 3)."

> In addition, a time course of the cell death observed in the infections may would also be helpful to evaluate their hypothesis that the increase of infected cells in the partially treated cells is due to increased infected cell survival -- i.e. decreased death.

As discussed in the response to the reviewer's general comment 3, we now include timelapse measurements of infection treated and untreated with the efavirenz which supports our hypothesis that the increase of infected cells in the partially treated cells is due to increased infected cell survival.

> 4\) Are the phenotypes described in the primary lymph node cells also observed for peripheral blood lymphocytes? Or are there differences between the peripheral blood versus the lymph node T cells.

As discussed in the response to the reviewer's general comment 4, the work we did perform on PBMCs showed little increase in infection with partial inhibition, consistent with the reviewer's intuition that this may be a lymph node specific effect.

> Reviewer \#3:
>
> This is an interesting and worthwhile paper that examines the effects of incomplete inhibition of HIV infection with reverse transcription inhibitors. The experimental results presented are in accordance with model predictions. However, the presentation of the model should be improved as detailed below. Also, I found the labeling and numbering of the supplemental figures confusing. I have no substantial concerns and this the paper should be published after minor revision.

We thank the reviewer for the support. We have clarified the model parameters and how they are measured as detailed in the responses to the Reviewer's specific comments below to address this very important point. We have ensured that all supplemental figures are labelled in *eLife* format and sequentially referenced in the text.

> 1\) The terms and concepts in the paper are not clearly defined. In the first paragraph of the Results, you mention each donor to target transmission. It is not clear what a transmission is. Does it refer to viral entry of either a free virus or a virus (or genome) by cell-to-cell transmission? It needs to be defined. Second define what you mean by infection. Does a cell have to produce virus to be considered infected? Does the virus have to integrate or is it sufficient to simply reverse transcribe? Is a latently infected cell an infected cell in your model? Also, when you say drug therapy increases the number of live infected cells do you mean live productively infected cells, live HIV DNA^+^ cells, etc.

The reviewer has identified an important gap in our presentation of the results which we have now corrected. We now present a table of definitions for each parameter in our system and how it is defined and measured. This now appears in the manuscript as Supplementary file 1.

We make extensive use of the sharpened definitions, including in the Results section:

"We introduce a model of infection where each donor to target transmission leads to an infection probability *r* and death probability *q* per infection attempt, where each model parameter is defined in Supplementary file \[...\] We define *L~λ~* as the probability of a cell to survive infection given λ infection attempts. Assuming infection attempts act independently, *L~λ~*=*(1-q)^λ^*."

> 2\) The assumption that all transmissions have equal probabilities to infect target cells seems to ignore the possibility that some virions carry defective genomes while others do not. This does not seem realistic. In your experimental system is the ratio of HIV RNA to TCID50 close to one so you can ignore defective particles?

Given that transmission is defined as the mean number of HIV DNA copies per cell and that this is what we measure, any virion which does not successfully reverse transcribe will not be detected. Therefore, the measurement of the number of transmissions per cell λ excludes virions defective in virus cycle stages leading up to an including reverse transcription. The fraction of defective viruses post-reverse transcription is captured in the term r, as HIV DNA copies with mutations which make them defective post-reverse transcription would not be able to produce viral proteins, our measure of successful infection. This is now described in the Results section:

"*r* and *q* capture the probabilities for a cell to be infected or die post-reverse transcription. For example, mutations which reduce viral fitness by decreasing the probability of HIV to integrate would reduce *r*, while mutations which reduce the probability of successful reverse transcription would reduce *λ*."

> 3\) You assume productive infection and death are independent events. While the events may be independent the probability of death is certainly not independent of whether a cell is productively infected or not. Further the probability of death is time dependent. The probability a cell dies one hour after viral entry (infection?) is clearly quite different than the probability it dies days after infection. You may want to define q as the probability a cell has died by time t after infection and the same for Pλ where t is 2 days or 4 days for your various experiments.

We thank the reviewer for bringing up the important point that cell death is a time-dependent process and the time-point at which it is quantified needs to be defined. We therefore corrected our definitions to state that the fraction of live infected cells is measured at 2 days post-infection for the cell lines and 4 days post-infection for lymph node cells, as the reviewer suggested. This now appears in Supplementary file 1 as discussed above.

> 4\) Results, second paragraph. You claim antiretroviral drugs reduce the number of infecting virions. This implies that by infecting you must mean the virus reverse transcribes. In standard viral dynamic models the effects of ART are to reduce the infection probability, i.e., r in your model not λ. Thus it is important to clarify your definitions.

The reviewer is correct that you would expect the effect of the reverse transcriptase inhibitor to be included in r. However, our measurable transmission λ is a reverse transcribed copy of HIV DNA. Hence in our model r accounts for the probability of a reverse transcribed viral genome successfully integrating into the host genome and producing viral proteins, which are independent of the action of efavirenz. The way we set up our model, the action of the reverse transcriptase inhibitor is on λ, not r. We address this as described in the response to point 2 of the reviewer's comments.

> 5\) You introduce the drug effect as a constant d in the second paragraph of the Results. Later in the paper you make reference to IC50 and Hill coefficients for the drug. These need to be tied together in an explicit manner. In viral dynamic modeling the effectiveness of a drug, epsilon, (eps) is introduced where eps=1 is a 100% effective drug, e.g. stops all reverse transcription, and where eps=0 means the drug has no effect. Then a pharmacodynamic model is used to relate eps with the drug concentration, C, e.g. eps= C\^n/(IC50\^n + C\^n). Thus rather than λ/d you could model the drug effect by (1-eps)λ and use the above formula to link the effect to drug concentration. See for example, Canini and Perelson, 2014. Equation 3 in your manuscript accomplished the same, but the above seems more straightforward.

The reviewer's notation is more elegant than what we use since it directly introduces the effect of drug per virus into the equation. The reason we would argue to keep our current notation is that d is on the same scale as λ, which we think makes a ratio such as d/λ more intuitive. Thus d=λ would reduce the infection to single HIV DNA copies per cell. We have stated the conversion between d and ε in the Materials and methods section:

"we used the relation for the fraction cells remaining infected in the face of drug (Canini and Perelson, 2014), whose definition is equivalent to *Tx* at *λ\<1*:

1d=1-=1-EFVhEFVh+IC50h (3)."

We also discuss the conversion in the Results section:

"This is equivalent to 1-ε in a commonly used model describing the effect of inhibitors on infection, where ε is drug effectiveness, with the 50% inhibitory drug concentration (IC~50~) and the Hill coefficient for drug action as parameter values (Canini and Perelson, 2014; Shen et al., 2008)."

> 6\) Results, fourth paragraph. When you measure the number of reverse transcribed copies of viral DNA I assume you are measuring both integrated and unintegrated DNA -- please state this explicitly as later you seem to imply you are measuring integrated DNA, e.g. Results, sixth paragraph.

We thank the reviewer for pointing out this omission and we now explicitly state that λ measures the number of HIV DNA copies, integrated and unintegrated. This is now reflected in Supplementary file 1 as described above, as well as in the Results section:

"In our experimental system, one infection attempt is measured as one HIV DNA copy, whether integrated or unintegrated."

> 7\) The current work focuses only on reverse transcriptase inhibitors. Model therapy uses combination therapy including integrase inhibitors and protease inhibitors. Expanding the discussion of the clinical implications of this work to include combination therapy would be worthwhile.

We agree with the reviewer that our analysis can be applied beyond reverse transcriptase inhibitors. We used efavirenz in our study due it being a common principal component of current first line antiretroviral therapy, with common drug resistance mutations. However, the infection optimum we describe should occur with other classes of antiretroviral drugs, since they all should decrease the multiplicity of infection between cells. We now include this point in the Discussion:

"We used EFV in our study since it is a common component of first line antiretroviral therapy, with frequent drug resistance mutations. \[...\]The more complex outcome of partial inhibition of infection should also be considered in other infections where multiple pathogens infect one cell and host cell death is a possible outcome (Mahamed et al., 2017)."

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> We want you to address the following comments. Note that we are not asking you to do further experiments. For the sake of record-keeping, we are enclosing all comments.
>
> Reviewer \#1:
>
> I am satisfied with their measurements.
>
> In general, I suggest breaking up long sentences (especially the one in Abstract, also the end of the third paragraph in the Introduction) for readability. Sentences that last more than three lines are generally more difficult to read than shorter sentences.

We have now broken up long sentences as follows.

Abstract:

"Using a computational approach, we found that partial inhibition of transmissions of multiple virions per cell could lead to increased numbers of live infected cells. If the number of viral DNA copies remains above one after inhibition, then eliminating the surplus viral copies reduces cell death."

Introduction:

"Multiple infections per cell have been reported in cell-to-cell spread of HIV (Baxter et al., 2014; Boull et al., 2016; Dang et al., 2004; Del Portillo et al., 2011; Dixit Perelson, 2004; Duncan et al., 2013; Law et al., 2016; Reh et al., 2015; Russell et al., 2013; Sigal et al., 2011; Zhong et al., 2013). In this mode of HIV transmission, an interaction between the infected donor cell and the uninfected target results in directed transmission of large numbers of virions (Baxter et al., 2014; Groppelli et al., 2015; Hubner et al., 2009; Sowinski et al., 2008)."

Introduction:

"Both modes occur simultaneously when infected donor cells are cocultured with targets. However, the cell-to-cell route is thought to be the main cause of multiple infections per cell (Hubner et al., 2009)."

Introduction:

"However, more recent work investigating markers associated with HIV latency in the face of ART found that the average number of HIV DNA copies per cell is greater than one in 3 out of 12 individuals. This occurred in the face of ART in the CD3 positive, CD32a high CD4 T cell subset (Descours et al., 2017)."

Introduction:

"We observed that partially inhibiting infection with drug or antibody resulted in an increase in the number of live infected cells in both a cell line and in lymph node cells. This is, to our knowledge, the first experimental demonstration at the cellular level that attenuation of HIV infection can result in an increase in live infected cells under specific infection conditions."

Results:

"To estimate this, we used PCR to detect the number of reverse transcribed copies of viral DNA in the cell by splitting each individual infected cell over multiple wells. We then detected the number of wells with HIV DNA by PCR amplification of the reverse transcriptase gene."

Results:

"This is equivalent to 1-ε in a commonly used model describing the effect of inhibitors on infection. In this model, is drug effectiveness, with the 50 percent inhibitory drug concentration (IC~50~) and the Hill coefficient for drug action as parameter values (Canini Perelson, 2014; Shen et al., 2008)."

Discussion:

"If each HIV DNA copy increases the probability of cell death, reducing the number of HIV DNA copies without eliminating infection should lead to an increased probability of infected cell survival. This would consequently lead to an increase in the number of live infected cells."

> Reviewer \#3:
>
> In this revised version on the paper the authors have clarified their definitions by incorporating a supplemental table and additional text describing their model. However, this clarification has raised the following issues that need to be resolved:
>
> 1\) As defined in the Results, λ is the number of infection attempts, where one attempt is measured as one HIV DNA copy. Thus, λ is an integer. The formula, Equation 1, makes sense when λ is an integer. However, what is determined experimentally is not the integer number of DNA copies but rather the mean number of copies per cell, which is not necessarily an integer. To make sense Equation 1 should be reformulated as a conditional probability of a cell being infected and alive given x attempts, call this P(I \| x). What I believe the authors want is the probability of a cell being infected and alive, which is then P(I) =Sum P(I \|x) (p(x)), where p(x) is the probability of having x infection attempts, and the sum is over all non-negative values of x. One could then assume, for example, that the number of attempts is Poisson distributed with mean λ. Then the resulting formula for P(I) would involve the mean value of the number of attempts. A better choice would be the empirical distribution that the authors measured. Note that what is actually measured is the number of infected cells that are alive at a certain time, i.e. P(I), and the mean number of attempts, what I called λ above.

We thank the reviewer for this comment. The reviewer is correct that our previous Equation 1 applies to infection attempts per cell, which are integer values. We have now reformulated the model to use the mean number of infection attempts, as described below and in the new Appendix 1: Supplementary Mathematical Analysis section. We used the Poisson distribution, the first suggestion of the reviewer, as we believe we need much more extensive experimental data to determine the exact empirical distribution.

We now consider the probability of a cell being infected and live given *n* HIV DNA copies, where n is an integer (Appendix 1-Equation 1).

If *P(n*) is Poisson with mean *λ*, the fraction of cells that are productively infected is as in Appendix 1-Equation 2.

We introduce a drug strength value *d*, where *d* = 1 in the absence of drug and *d \>* 1 in the presence of drug. In the presence of drug, *λ* is decreased to *λ/d*. The drug therefore tunes *λ*. The probability of a cell to be infected and live given drug strength d is therefore as in Appendix 1-Equation 3.

Appdenxi 1-Equation 3 is now used to derive Figure 1, which is qualitatively similar to Figure 1 from the previous submission using Equation 2. The range of *q* values was modified to show the full range of infection behavior with the new model (Figure 1)

Experimentally, we measure *P~λ~*, the number of infected cells, and *L~λ~*, the number of live cells remaining two days post infection for the cell line.

Assuming a Poisson distribution of the number of infection attempts, the probability of being productively infected is as in Appendix 1-Equation 4.

Similarly, the probability of a cell to live is as in Appendix 1-Equation 5.

The derivation of the model above is included in the new Supplementary Mathematical Analysis section. The new definition of *P~λ~*and *L~λ~*is now updated in Supplementary file 1.

The experimentally determined values for *r* and *q* are now recalculated to be *r* = 0.28 and *q* = 0.15. This is now updated in Supplementary file 2.

Comparing this model to the model described by the previous model (Equation 2 in the previous submission), we note that the models give very similar results at *λ \>* 1, but that our previous model underestimates the rate of decline in infection at *λ \<* 1, as shown in [Author response image 1](#respfig1){ref-type="fig"} for L100I HIV mutant coculture infection of the cell line, where the effect was most pronounced.

![](elife-30134-resp-fig1){#respfig1}

To investigate whether the experimental results were above the fit line due to technical factors, we refined our experimental approach to exclude donor cell -- target cell fusions, which may give a baseline in the infection. In the previous submission, we judged the fraction of fusions to be negligible and selected on target cells based on mCherry fluorescence. Here, we used the vital stain Cell Trace Far Red (CTFR) to label donor cells. Target cells still expressed mCherry. We therefore selected target cells based on mCherry, but excluded any target cells which were CTFR and mCherry double positive. Due to the extra fluorescence channel, it was necessary to change from our previous death detection dye with far-red emission (DRAQ7) to the blue spectrum emission death detection dye (DAPI). For this, we used a different flow cytometer (FACSAria Fusion) which had the 355nm laser for DAPI excitation. The gating strategy is now illustrated in Figure 2--- Figure supplement 4 for wild type HIV infection.

It is described in the Results section: "To obtain the number of infected target cells, and specifically exclude donor cells or donor-target cell fusions, target cells were marked by the expression of mCherry. \[...\] Donor-target cell fusions were excluded by excluding CTFR positive cells (see Figure 2--- figure supplement 4 for gating strategy)." The results shown in Figure 2--- figure supplement 4 are described in the Results section:

"While the percent of infected cells was reduced with drug, the concentration of live infected cells increased (Figure 2---figure supplement 4)."

We also describe the method in the Materials and methods section:

"To determine the number of live infected cells in reporter cell line experiments, E7 RevCEM reporter cells were infected as above used as donor cells. \[...\] The coculture infection was pulsed with 100ng/ml DAPI (Σ) immediately before flow cytometry and the number of live infected targets cells was determined by the number of DAPI negative, CTFR negative and mCherry and GFP double positive cells on a FACSAria Fusion machine (BD Biosciences) using the 355, 488 and 633nm laser lines."

We used the same approach for infection with the L100I HIV mutant, and the gating strategy is illustrated in the new Figure 3---figure supplement 2.

We describe the new figure in the Results:

"We next performed coculture infection (see Figure 3---figure supplement 2 for gating strategy)."

We also increased the number of data points for wild type and mutant infections in the cell line when we repeated the experiments. The number of data points increased from 5 to 7 for wild type HIV infection, and 6 to 8 for L100I mutant infection of the cell line (3 independent experiments each). For mutant infection, we concentrated on drug concentrations closer to the peak since that was the region with the most pronounced decline in infection. Excluding donor-target cell fusions using new gating strategy resulted in an incremental improvement to the data, as shown in [Author response image 2](#respfig2){ref-type="fig"} for wild type mutant HIV infection in the cell line:

![](elife-30134-resp-fig2){#respfig2}

These new results showed that the lower than expected decline in infection at high drug concentrations was not a technical artifact due to a baseline of infected donor cells which were fused to targets. This deviation from the model at high drug concentrations away from the peak infection with drug is now noted in the Results section:

"We note that both wild type and mutant coculture infection has data points above the fit line at the highest drug concentrations. This may be a limitation of our model at drug values much higher than observed at the infection optimum. In this range of drug values, our model predicts a more pronounced decline in the number of infected cells than is observed experimentally."

We also include the observation in the Discussion section:

"Neither model accurately captures infection dynamics at high drug concentrations, away from the infection optimum. In this range, where the number of infection attempts per cell is much lower than 1, infection declined more slowly with drug than predicted."

We feel this observation may be potentially important to understanding the HIV reservoir. However, the existence of a fitness optimum with drug is a separate issue, and our current model successfully describes how the fitness optimum is formed.

An important conclusion reached when we compared the fits before and after fusion exclusion, as well as the fit of the previous iteration of L100I mutant infection to the current experiments, is that small differences in the experimental data resulted in large differences in the value of *r*. Hence, *r* did not seem to be well constrained in the fits. As shown in Figure 1, *r*determines the amplitude of *P~λ~*. This is now emphasized in the Results section:

"Hence, the value of *r* strongly influences the amplitude of *P~λ~*."

To better constrain *r* as a result of these new observations, we switched from normalizing the number of infected cells and *P~λ~*to the maximum value in each case to using the number of live infected cells per ml. For this, the *P~λ~*predicted by the model was multiplied by the number of target cells at the start of infection, which was 10^6^ cells/ml. The best fit for the model as well as the result of the calculation with the experimentally determined *r* and *q* is shown in updated Figures 2 and 3 as Figure 2D (wild type infection) and Figure 3B (L100I mutant infection).

The great improvement of this approach is that *r* values are now constrained: *r* = 0.22 and *q* = 0.17 for wild type HIV cell line infection and *r* = 0.29 and *q* = 0.13 for L100I mutant cell line infection. This now compares well with the experimentally determined *r* = 0.28 and *q* = 0.15. The new analysis is described for wild type infection in the Results section:

"While the percent of infected cells was reduced with drug, the concentration of live infected cells increased (Figure 2---figure supplement 4). \[...\] Equation 3 best fit the behaviour of infection when r=0.22 and q=0.17, resulting in a peak at 4.8nM EFV (Figure 2D, black line)."

It is described for cell line infection with mutant L100I virus in the Results section:

"The fits recapitulated the experimental results when *r* = 0.29 and *q* = 0.13, with a fitted peak at 45nM EFV (Figure 3B, black line). The solution to Equation 3 using the measured values for r and q showed a similar pattern to that obtained with the fitted values (Figure 3B, dashed green line)."

We applied the new model to the coculture lymph node infection results. However, we could not use the number of live infected cells to constrain *r* in this case, since we do not know the number of infectable targets. This is because the lymph node is a complex environment containing, besides CD4^+^ T cells of various kinds and potentially infectable APCs, also CD8^+^ T cells and B cells. This is now discussed in the Results section:

"We did not calculate the predicted number of infected cells for *P~λ~/d* values since the lymph node is a complex environment containing different cell subsets (Sallusto et al., 1999) and the number of infectable target cells at the start of infection is difficult to determine. Hence, we normalized both the experimental number of live infected cells and the *P~λ~/d* values from Equation 3 to the maximum value in each case."

The results of the new fit are presented in Figure 6B.

For this fit, *r* = 0.91 and *q* = 0.15. While *q* matches the measured cell line result well, the *r* is high. We believe this because it is poorly constrained in the fit, as discussed in the Results section:

"The fits recapitulated the experimental results when *r* = 0.91 and *q* = 0.15, with a fitted peak at 90nM EFV (Figure 6B, black line). \[...\] However, the fitted r value in this case is not expected to be accurate since we were unable to constrain it with the number of infected cells relative to the starting number of target cells."

> 2\) According to the model q should be independent of the number of attempts. Can this be tested by using different drug concentrations, which would vary the mean number of attempts? If you already have experimental data on this, then include them. Otherwise, just discuss it.

We thank the reviewer for the insightful comments and agree that the probability to die per infection attempt may depend on how many previous infection attempts occurred in the same cell. We discuss this point in the Discussion section:

"Moreover, the probability of death per HIV DNA copy we denote *q* may be dependent on how many infection attempts preceded the current infection attempt, and the model can be improved by measuring this dependence."

> 3\) In the original manuscript where Equation 1 was derived the authors assumed q was independent of r. In the second paragraph of the Results the authors say q is the probability of a cell to die post reverse transcription, which seems more sensible to me. Under the original assumption of q and r being independent, a cell in which the attempt was unsuccessful would have the same probability of dying as a cell in which reverse transcription succeeded. With q now defined as in the second paragraph of the Results, the fundamental formula given by Equation 1 may not be correct and deserves a more thorough discussion. I think the fundamental process being described is that at each attempt a cell is either infected with probability r, or not infected with probability 1-r. If it is infected, i.e. had a successful reverse transcription, then with probability q it remains alive and with probability 1-q it dies. Assume there are x attempts. Let z be the number of cells infected after x attempts. Then z is binomially distributed, i.e. z= Bin (x,r). Further, if we are interested in the number of cells infected and alive after x attempts, then P(I\|x) = Sum_z=1 to x (x choose r) r\^z (1-r)\^(x-z)(1-q)\^z, where the factor (1-q)\^z is the probability of a cell surviving after each of the z infections. Simplifying, P(I\|x) = \[r(1-q) + (1-r)\]\^x, which is not the same as Equation 1. The number of attempts, x, is again random and as above one can convert this conditional probability into P(I) by assuming a Poisson (or some other distribution such as the empirically measured one) for the number of attempts p(x).

We thank the reviewer for the comment which essentially questions whether the probability of death needs to be independent of the probability to infect for an infection optimum with drug to exist. We have now constructed a second model where death is dependent on infection.

In the case where cell death depends on productive infection, the probability of productive infection and survival of the cell given *n* attempts is shown in Appendix 1-Equation 6.

Here, *r*^0^and *q*^0^are the probabilities for infection and death respectively. Their relationship to the experimentally measured *r* and *q* are discussed in the next section. *r*^0*m*^(1 − *q*^0^)*^m^*is the probability that *m* infection attempts are successful and none of the attempts triggers cell death, while (1 − *r*^0^)*^n^*^−*m*^accounts for *n* − *m* unsuccessful infections.

Realizing that (Appendix 1-Equation 7) we can simplify to Appendix 1-Equation 8.

Averaging this over a Poisson distribution with mean *λ*, we find Appendix 1-Equation 9.

The two models are the same if: (Appendix 1-Equation 10).

In this case the two models are a re-parametrization of the same process. The experimental measurement of *r* and *q*, as described in the main manuscript, consists of estimating *r* as the fraction of infected cells when the fraction of dead cells is low due to a low number of measured DNA copies per cell. *q* is derived by measuring the number of live cells remaining when the number of HIV DNA copies per cell is known. If the probability of death is dependent on infection, then death is only of infected cells and is a product of the probability to be infected and die (*r*^0^*q*^0^). Likewise, the underlying probability of infection *r*^0^will account for the fraction dead cells (*q*) and any cells which are infected but not dead (*r*(1 − *q*)). We therefore conclude that independence of cell death and successful infection is not a required condition for a fitness optimum. This is now stated in the Results section:

"Our model assumes that cellular infection and death due to an HIV infection attempt are independent processes. \[...\] The models are equivalent, showing that independence of cell death and infection is not a necessary condition for an infection optimum to occur in the presence of inhibitor."

We also discuss the result in the Discussion section:

"Construction of the model assumed independence of productive infection and cell death. However, as shown in the Supplementary Mathematical Analysis section, an equivalent model can be constructed assuming a dependence of cell death on infection."

The derivation of the above model is included in the new Supplementary Mathematical Analysis section.

> 4\) In Supplementary file 1 the authors say the way they measure the probability a cell is alive after λ attempts is by computing the concentration of cells alive with λ attempts divided by the concentration of cells alive with no transmissions. However, since the concentration of cells alive with no transmissions can approach zero as time goes on it is clear that this fraction need not be less than 1. Also, as noted above the authors need to use conditional probabilities and derive formulas that involve the mean number of attempts. I would suggest they compute the ratio of the probability a cell is infected to the probability a cell in not infected and alive, which is what they measure, and see if they can derive a formula for q.

If we understand the reviewer's comment correctly, the reviewer's concern is that the concentration of cells alive with no transmissions approaches zero because both are measured simultaneously in the same culture. However, we set up the experiment differently, where cells equally exposed to all infection conditions except HIV DNA copies were compared for cell death. This was accomplished by treating one of two separate infected cell cultures with EFV at a concentration which resulted in almost complete inhibition of cell-free infection, the mode of infection used. We have now clarified this in the caption of Figure 2---figure supplement 5. Experimental measurement of r and q:

"The concentration of live cells two days post cell-free infection was measured using trypan blue exclusion and divided by the concentration of live reporter cells in a separate cell culture infected with the identical amount of virus, but with infection was inhibited with 40nM EFV."

We have also included a clarification in Supplementary file 1, which states how the fraction of live cells remaining *L~λ~*is measured.

[^1]: ^\#^These authors contributed equally to the work.
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